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Nonribosomal peptides represent an extensive family of small-
molecule natural products, including antibiotics, anticancer
agents, immunosuppressants, enzyme inhibitors, siderophores,
herbicides, antifungals, insecticides, and anthelminthics. Non-
ribosomal peptides are biosynthesized on giant multi-domain
enzymes called nonribosomal peptide synthetases (NRPSs).1–4
The core domains of NRPSs include those that are responsibleNat. Prod. Rep., 2011, 28, 99–124 | 99
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View Article Onlinefor the recognition and activation of the precursors by adeny-
lation using ATP as the co-substrate (A¼ adenylation domains);
those that capture the precursor adenylates as covalent thioesters
via a phosphopantetheine linker (T ¼ thiolation domains); and
those that catalyze the condensation of the growing peptide
chain, covalently bound to the previous T domain, with the
precursor thioester by amide or ester bond formation (C ¼
condensation domains). NRPSs may also feature active site
domains for the modification of the precursors and/or the
intermediates by N-methylation (M domains), oxidation/Roderich S€ussmuth
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100 | Nat. Prod. Rep., 2011, 28, 99–124reduction (Ox and KR domains), epimerization (E domains) and
heterocycle formation (Cy ¼ cyclization domains); and for the
release and the cyclization (if necessary) of the final products
from the enzymes (TE ¼ thioesterase, or R ¼ reductase domain,
or a terminal C domain). These domains are organized into
modules in the NRPS mutlitenzymes. In linear (Type A) NRPSs,
each module, and each active site domain is used only once in an
assembly line fashion (processive NRPSs). In rare cases viola-
tions to this rule may be observed, for example as in module
skipping.5,6 In contrast, iterative (Type B) NRPSs use some ofHans von D€ohren
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View Article Onlinetheir modules more than once in a programmed iterative fashion.
Finally, nonlinear (Type C) NRPSs feature unusual arrange-
ments of their core domains and often incorporate precursors
that are not tethered on carrier domains.7
The tremendous structural variety of nonribosomal peptides is
based on the flexibility of the biosynthetic programming of the
NRPS: the utilization of non-proteinogenic amino acid precur-
sors (more than 300 described); the formation of main-chain
heterocycles (thiazole, oxazole and their derivatives); and the
construction of linear, macrocyclic or branched macrocyclic
structures with amide, ester or even thioester or imino ring
closures.4,8 In the scaffold of the nonribosomal depsipeptides, at
least one bond of the peptide backbone is replaced by an ester
bond: these connect carboxy groups of amino acids with a 2-
hydroxycarboxylic acid, or provide alternative routing of the
chain via side chain hydroxy groups of amino acids and the C-
terminus of the peptide. The structural complexity of non-
ribosomal (depsi)peptides is further enhanced by the installation
of N-terminal aryl or alkyl caps, lipid or glycosyl side chains, and
the formation of intramolecular bridges (disulfide bridges,
oxidative coupling between side chains), as catalyzed by ‘‘deco-
rating’’ enzymes.9
Cyclooligomer nonribosomal peptides consist of oligopeptide
or, in the case of cyclooligomer depsipeptides (CODs), oligo-
peptidol monomer units that undergo recursive head-to-tail
condensation, or oligomerization via side chains, followed by
macrocyclization.8 The corresponding NRPSs form a subclass of
Type B NRPSs. These NRPSs use their modules iteratively for
the biosynthesis of several copies of identical or nearly identicalThis journal is ª The Royal Society of Chemistry 2011peptide/peptidol monomer units that remain covalently bound
on the enzyme. These enzymes also evolved mechanisms for the
recursive, stepwise intermolecular ligation and final intra-
molecular cyclization of the monomer units in a concerted
cyclooligomerization process.
Fungal CODs, the subject of the current review, are privileged
pharmacophores that display a wide variety of bioactivities,
including antibiotic, insecticidal, anthelminthic, herbicidal, anti-
retroviral, cytotoxic, anti-haptotactic, and chemosensitizer
activities, as well as inhibition of cholesterol biosynthesis, and
repression of amyloid plaque formation in Alzheimer’s disease.
Fungal COD biosynthesis has been characterized first by
isolating and reconstituting active cyclooligomer depsipeptide
synthetase (CODS) enzymes from the producer fungi, and later
by isolating, characterizing and heterologously expressing the
encoding synthetase genes. New fungal CODS genes were
discovered by genome mining, and interesting mechanistic
differences were noted for CODS of fungal versus bacterial
origin. Novel analogs of fungal CODs have been generated by
a variety of combinatorial biosynthetic methods, including
precursor-directed biosynthesis, mutasynthesis, combinatorial
mutasynthesis, and total biosynthesis.
2 Cyclooligomer depsipeptides in fungi: Structure,
distribution, biological activities
CODs display a rotational symmetry as a result of their oligo-
meric structure: CODs are biosynthesized as dimers, trimers or
tetramers of monomer units, each of which are formed from atNat. Prod. Rep., 2011, 28, 99–124 | 101
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View Article Onlineleast one 2-hydroxycarboxylic acid and one 2-amino acid.
Beauvericin (1), enniatins (2), bassianolide (3) and PF1022A (4)
and its congeners contain residues with alternating D and L
configuration, similar to 6–8-member cyclic D,L-a-peptide anti-
bacterial agents.10,11 Variations in the amino acid or the
hydroxycarboxylic acid positions of the monomers lead to the
production of various COD congeners in a given COD producer
fungus. COD production in fungi has hitherto been only docu-
mented in the Hypocreomycetidae and the Xylariomycetidae,
two subclasses of the Sordariomycetes.
Cyclodepsipeptides showing a pseudo-cyclodimeric structure
have also been isolated from several Dothiodeomycete Pith-
omyces spp. (teleomorph: Leptosphaerulina spp.). The cyclo-
tetradepsipeptide angolide12 (5) and the cyclohexadepsipeptide
sporidesmolides13 (6) are apparent dimers of a dipeptidol
(angolide) or a tripeptidol (sporidesmolides). However, the
exclusive utilization of D amino acids in one half of these mole-
cules, and L amino acids in the other half, argues against their
origin from cyclodimerization (see Section 4.9).2.1 Cyclohexadepsipeptides: Beauvericin
Beauvericin (1) is a cyclic trimer of a dipeptidol monomer. This
dipeptidol is formed from (2R)-2-hydroxy-3-methylbutanoic
acid (D-hydroxyisovaleric acid, D-Hiv) and N-methyl-L-phenyl-
alanine (N-Me-Phe). Beauvericin is produced by many Fusarium
species in the Gibberella fujikuroi complex, and it is also the main
fermentation product of the hypocrealean entomopathogens
Beauveria bassiana, Paecilomyces fumoso-roseus (renamed Isaria
fumosorosea), and P. tenuipes (renamed I. tenuipes).14–17 Beau-
vericin production was suggested as a diagnostic feature for
a clade in the genus Isaria, represented by strains of I. cicadae, I.
fumosorosea, I. japonica, and I. tenuipes, as well as the Cordyceps
(teleomorph) state of I. cicadae.18 Interestingly, co-production of
beauvericin with enniatins H, I and MK 1688 was observed in
Fusarium oxysporum FB1501.19 Beauvericin and the enniatins (2,
see below) transport mono- and bivalent cations across
membranes as free carriers and uncouple oxidative phosphory-
lation, with a 2:1 depsipeptide:cation sandwich as the mobile
species.20 The degree to which this common ion transporter
activity is responsible for the disparate biological activities of
beauvericin and the enniatins is currently unknown.
Beauvericin is toxic to brine shrimp and to the larvae of
insects,16,21 and acts as an important virulence factor during insect
pathogenesis byB. bassiana.22 It also displaysmoderate antifungal
activity, and antibiotic activity against Gram-positive bacteria.21
Beauvericin is a low-micromolar inhibitor of acyl CoA:cholesterol
acyltransferase (ACAT, EC 2.3.1.26): inhibition of this enzyme
leads to decreased plasma cholesterol levels.23,24 ACAT inhibition
also suppresses proteolytic processing of the b-amyloid precursor
protein, thereby reducing amyloidplaque density in animalmodels
of Alzheimer’s disease.25,26 A recent publication showed that
beauvericin, as well as enniatin I and enniatin MK 1688, exhibit
strong in vitro inhibitory activity against the type-1 human
immunodeficiency virus (HIV-1) integrase, but not against the
Moloney murine leukemia virus reverse transcriptase.27
Beauvericin also reverses the multidrug-resistance (MDR)
phenotype in yeast and potentiates the fungicidal activity of
fluconazole against fluconazole-resistant Candida albicans at102 | Nat. Prod. Rep., 2011, 28, 99–124concentrations that are not directly fungicidal.28–30 Synergistic
activities amongst different antibiotics are well known (i.e.
streptogramin A and B components), but compounds that show
only weak antibiotic or antifungal activity themselves might also
increase the potency of bona fide antibiotics or antifungals. These
potentiators or sensitizers might prevent the inactivation of the
antibiotic or antifungal agents, and facilitate the penetration or
inhibit the active efflux of these agents through the cell envelopes
of the pathogens.31
Beauvericin was also shown to act as a potentiator of cytotoxic
drugs in multidrug-resistant (MDR) cancer cell lines. Over-
expression of P-glycoprotein (Pgp), an ABC superfamily trans-
porter, is a prominent cause of multidrug resistance in human
cancers. Beauvericin was shown to directly bind to purified Pgp
with an apparent KD of 0.36 mM, and to inhibit the drug trans-
port function of Pgp in membrane vesicle preparations at 1 mM.
Beauvericin restored daunorubicin accumulation in the Pgp-
overexpressing MDR Chinese hamster ovarian cell line CHRC5
at sub-cytotoxic concentrations.32
Beauvericin displays potent cytotoxic activity against
different human cell lines.33 Beauvericin increases cytoplasmic
Ca2+ concentration, causes ATP depletion, and activates
calcium-sensitive cell apoptotic pathways.34,35 At sub-cytotoxic
concentrations, beauvericin inhibits the haptotactic motility of
cancer cells.36 Formation of new blood vessels in tumors
(angiogenesis), tissue invasion by cancer cells, and metastasis all
involve haptotaxis (directional cell motility).37 In contrast,
haptotaxis is rather infrequent in adults under ordinary physi-
ological conditions.38 Inhibition of angiogenesis is a validated
cancer chemotherapeutic strategy as shown by thalidomide and
bevacizumab, and is one of the established mechanisms of
action of the marketed drugs sunitinib, sorafenib, and pacli-
taxel.39,40 Inhibition of tissue invasion and metastasis might
restrain new tumor formation, or increase successful contain-
ment of solid tumors. The cytotoxic and the anti-haptotactic
activities of the taxanes41 and the Vinca alkaloids42 have distinct
mechanisms of actions.2.2 Cyclohexadepsipeptides: Enniatins
Enniatins (2) are prevalent fungal mycotoxins from Fusarium
spp.43,44 that are also produced by Verticillium hemi-
pterigenum45,46 and Halosarpheia sp.47 Enniatins feature similar
trimeric structures to that of beauvericin, with D-Hiv as the
hydroxycarboxylic acid constituent of the dipeptidol monomer.
However, the aromatic N-Me-Phe moieties featured in the
beauvericin dipeptidol monomers are replaced by aliphatic N-
Me-Ile (enniatin A), N-Me-Val (enniatin B) or N-Me-Leu
(enniatin C). Enniatins act as ionophores by forming freely
diffusible sandwiches in biological membranes,48 and display
similar activities to that of beauvericin, including anthelminthic,
phytotoxic, antibiotic, antifungal, ACAT inhibitory, cytostatic
and cytotoxic activities.24,33,43,49 Several studies have compared
the biological activities of beauvericin and the enniatins, e.g. with
regard to cytotoxicity and accumulation in cells, the latter of
which was found higher for beauvericin than for the enniatins.50
No resistance was found in two-year continuous exposure studies
in human nasopharyngeal carcinoma KB-31 cell lines against
beauvericin, and only a low level of resistance developed againstThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlineenniatins. Multidrug-resistance exporters were found to be
induced in the selected enniatin-resistant cell lines, and these cells
also showed cross-resistance to other chemotherapeutics. In
contrast, enniatins were found to restore the antifungal activity
of cycloheximide or cerulenin against multidrug-resistant
Saccharomyces cerevisiae at non-toxic concentrations, due to
their specific inhibition of the ABC-transporter Pdr5p.51 Fusa-
fungin, a mixture of various enniatins (enniatin A, B and C), with
antimicrobial activity against several Gram-positive and Gram-
negative bacteria and Candida albicans, is currently used as
a topical agent for the treatment of respiratory infections.52
Enniatins have also been shown to act as virulence factors for the
plant pathogen Fusarium avenaceum.53
2.3 Cyclohexadepsipeptides: Hirsutellide A
Hirsutella kobayashii, a hypocrealean entomopathogenic fungus,17
produces the antimycobacterial and antimalarial metabolite hir-
sutellideA (7).54Asopposed tobeauvericin (1) and the enniatins (2),
this cyclohexadepsipeptide is a dimer of the tripeptidolmonomer D-
2-hydroxy-3-phenylpropanoic acid–L-allo-isoleucine–N-methyl-
glycine, andnot a trimerof adipeptidolmonomer.Thebiosynthesis
of this cyclohexadepsipeptide has not yet been characterized.
2.4 Cyclooctadepsipeptides: Bassianolide
Bassianolide (3) is a cyclic octadepsipeptide isolated from the
hypocrealean entomopathogens Beauveria bassiana and Leca-
nicillium sp. (formerly Verticillium lecanii),17 and from the
wood-decaying Xylaria sp. BCC1067.55 Its 24-membered mac-
rolactone ring is formed as a tetramer of the dipeptidol
monomer D-Hiv–N-Me-Leu. This is the same monomer unit
that yields enniatin C upon trimerization in Fusarium sp. Bas-
sianolide was shown to be toxic to insect larvae,56 and repre-
sents an important virulence factor of B. bassiana during insect
pathogenesis.57 Bassianolide inhibits acetylcholine-induced
smooth muscle contraction in a manner that does not involve
ionophoric interactions.58 Bassianolide was moderately or
weakly toxic to different cancer cell lines in vitro, but showed no
anti-haptotactic activity.55,57
2.5 Cyclooctadepsipeptides: The PF1022 congeners
PF1022A (4) and its congeners are produced by Mycelia sterilia
(an unidentified fungal strain growing only as mycelium with noThis journal is ª The Royal Society of Chemistry 2011observed production of conidia),59 later identified as Rosellinia
sp. (Xylariaceae).60 The PF1022s are built from the hydroxy-
carboxylic acids D-Lac or D-PheLac, and the amino acid
N-Me-Leu. The main metabolite PF1022A has a C2-symmetry
and is formally composed of two tetradepsipeptides. However,
other PF1022 congeners have been described with various
combinations of D-Lac and D-PheLac, thus indicating a relaxed
incorporation of hydroxycarboxylic acids into dipeptidols that
undergo cyclotetramerization during PF1022 biosynthesis.61 The
PF1022s are highly potent anthelminthics with no significant
insecticidal activity, and low toxicity to mammals. They cause
flaccid paralysis in nematodes in a novel mechanism that involves
binding to latrophilin-like receptors at nanomolar IC50 concen-
trations, and the inhibition of calcium-activated potassium
channel-dependent (SLO-1) signaling pathways.62 Some semi-
synthetic cyclooctadepsipeptides of the PF1022 series, especially
those such as emodepside with para substitutions in their phe-
nyllactic acid moiety, are even more active than natural
PF1022s.63 Considerable work has been carried out on defining
the structure–activity relationships of PF1022 derivatives. In
early approaches, a systematic exchange of the amino acid N-
Me-L-Leu by a series of related N-alkyl amino acids was per-
formed, shifting the b-carbon or the g-carbon substituents to
higher hydrophobicities. The resulting activity data strongly
suggest that N-Me-L-Leu is crucial for high in vivo activity.64
Remarkably, the exchange of the carbonyl oxygen with sulfur
resulted in increased activity,65 and more recent findings point
towards biosynthetic options for future introduction of this
modification.66 In addition, the depsipeptide backbone confor-
mation influences anthelminthic properties, as demonstrated by
a systematic exchange of the dipeptidols by b-turn mimetics, e.g.
D-Pro–L-Pro. In this case, increased activity was only observed
with derivatives in which the D-PheLac–L-Leu dipeptidols were
replaced in a manner that retained the conformation of the PF
1022A parent molecule, whereas other variants led to decreased
anthelminthic activity.67 PF1022A and its semisynthetic deriva-
tives are effective against benzimidazole-, levamisole- and iver-
mectin-resistant gastrointestinal parasitic nematodes.68 Since
such resistant parasites are rapidly spreading in sheep, cattle,
horses and pigs, drugs such as the PF1022 derivatives which
display a new mode of action, are urgently needed.63 Semi-
synthetic PF1022 derivatives are also considered as next-gener-
ation treatments for human parasitic nematode infections such
as river blindness, where resistance to the current standard-of-
care ‘mectin’ class of drugs is increasing.69 Unfortunately, the
chemical synthesis of CODs suffers from several shortcomings:
the hydroxy groups from the 2-hydroxycarboxylic acids are less
nucleophilic towards facile ester formation by methods
commonly applied in peptide chemistry; racemization of the
amino acids and hydroxycarboxylic acids is frequent; and the
coupling efficiency of N-methyl amino acids is reduced. As
a consequence, synthetic approaches do not at present appear to
be an economical means for the commercial production of
PF1022 derivatives for use as drugs.702.6 Cyclooctadepsipeptides: Verticilide
Verticilide (8) was isolated from the hypocrealean fungus Verti-
cillium sp. FKI-1033, on the basis of its inhibition of the bindingNat. Prod. Rep., 2011, 28, 99–124 | 103
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View Article Onlineof ryanodine, a plant alkaloid, to the insect ryanodine receptor.71
This receptor is a Ca2+ release channel in the sarcoplasmic
reticulum, and has been identified as a potential target for new
insecticides. Verticilide is a cyclotetramer formed from the
dipeptidol D-2-hydroxyheptanoic acid–N-methyl-L-alanine. The
biosynthesis of verticilide has not yet been elucidated.
2.7 Diketomorpholines: Bassiatin and lateritin
Intramolecular cyclization of a single D-Hiv–N-Me-L-Phe
monomer unit (the same monomer that yields beauvericin upon
cyclotrimerization) yields the morpholine-2,5-dione bassiatin
(9), isolated from Beauveria bassiana. Bassiatin inhibits the
ADP-induced aggregation of rabbit platelets,72 but was found to
show no significant activity in a cytotoxicity assay with CCRF-
CREM human leukemia cells.34 The diastereoisomer of bassia-
tin, the acyl-CoA:cholesterol acyltransferase inhibitor lateritin
(10), was isolated from Isaria japonica, Gibberella lateritium,
and an endophytic Fusarium sp.73–75 Lateritin was also produced
in a mixed fermentation involving five different filamentous
fungi, including Fusarium oxysporum which might be the de
facto producer of this compound.76 Lateritin showed antibac-
terial, antifungal and cancer cell cytotoxic activities.76 The
structure and co-occurrence of these compounds in fungi that
also produce CODs raises the possibility that these diketo-
morpholines are not bona fide independent biosynthetic
metabolites, but simply derailed shunt products of COD
biosynthetic pathways.
2.8 CODs in bacteria
Cyclooligomer peptides (for example, gramicidin S) and dep-
sipeptides (for example, enterobactin) are also biosynthesized by
bacteria from peptide or peptidol monomer units.8,77 The ester
bonds in the macrocycles of the bacterial CODs are formed
either by ligation of peptidol monomers via the 2-hydroxy
groups of hydroxycarboxylic acids (e.g., valinomycin, cereulide,104 | Nat. Prod. Rep., 2011, 28, 99–124and serratomolide) as in fungal CODs, or by cyclo-
oligomerization of peptide monomers via the side chain alcohols
of amino acids (e.g., enterobactin, triostin, echinomycin, and
quinomycin).3 Survey of COD biosynthetic systems in fungi
3.1 Enzyme isolation and stability
Isolation of fungal multienzymes was pioneered in the Kleinkauf
laboratory, starting with the enniatin, beauvericin and cyclo-
sporin synthetases.78–80 The strategy consisted of (1) obtaining
a suitable producer strain, possibly improved by random muta-
genesis; (2) determining the production phase within the
fermentation process employed; (3) disrupting the fresh or frozen
mycelial suspension at 4 C by a French press, or the frozen
mycelia by grinding in liquid nitrogen; (4) nucleic acid precipi-
tation by poylethylene imine solution; (5) fractionated salting out
of proteins using ammonium sulfate; and (6) further standard
protein purification steps. These included gel filtration (as the
large multienzymes may be well separated), ion exchange chro-
matography on DEAE-cellulose, hydrophobic interaction chro-
matography (most commonly propyl- or butyl-agarose), and
sucrose gradient centrifugation. To further concentrate the
enzyme, the fractions were passed through size selective filters.
The enzyme preparations could be stored frozen at80 C in the
presence of glycerol. In the case of the ESYN enniatin synthetase,
the pure enzyme could be stored at the previously described
conditions for several years without significant loss of activity.
The specific protocols varied with the strains used, the properties
of the mycelia, the modes of cell disruption, and the enzyme
content. Detailed protocols were established for enniatin
synthetases from Fusarium equiseti (synonym: F. scirpi, previ-
ously described as F. oxysporum),79 F. sambucinum and F. lat-
eritium;81 for the beauvericin synthetase from Beauveria
bassiana;82 and for the PF1022 synthetase from Mycelia sterilia
(Rosellinia sp.).61 These CODS have been purified to homoge-
neity as judged by SDS polyacrylamide electrophoresis, and their
molecular masses have been estimated by gel filtration, sucrose
gradient ultracentrifugation and electrophoretic mobilities. Since
reference proteins in the high mass range (300–400 kDa) were
either not available at the time, or their masses were poorly
determined, the first estimates for their size (250 kDa) turned out
to be well below the accurate masses later confirmed by analytical
ultracentrifugation and DNA sequencing.
The purity of the enzyme preparations was monitored by
in vitro formation of CODs upon supply of substrates (amino
acid and hydroxycarboxylic acid), Mg2+, ATP and SAM. The
common reaction times were up to one hour at 25 C, usually
with complete loss of activity. The half lives of the enzyme
preparations were found to be diverse, ranging from 12 h at 0 C
for the PF1022 synthetase61 to 50 h at 25 C for the enniatin
synthetase.83 Generally, protease content was a limiting factor,
and proteinase inhibitors were found to be essential for stabili-
zation (H. Peeters, Doctoral Thesis, TU Berlin, 1988). Reported
catalytic activities range from 2 pkat mg1 (beauvericin synthe-
tase) and 12 pkat mg1 (PF1022 synthetase) to 100 pkat mg1 for
the enniatin synthetase. This highest activity corresponds to
a turnover number of 2 catalytic cycles/min.This journal is ª The Royal Society of Chemistry 2011
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View Article Online3.2 Reconstitution of COD biosynthesis in vitro with purified
CODS enzymes (‘‘total biosynthesis’’)
The in vitro reconstitution of enniatin synthesis clearly demon-
strated that all reactions required for COD assembly are per-
formed by a single multienzyme, which is a multifunctional
synthetase.84 This has been confirmed for all other CODSs
studied to date,61,79 and can also be concluded independently
from their identical domain organization. Substrate require-
ments reveal the overall reaction
3 AA + 3 HA + 3 SAM + 6 ATP/
COD + 6 AMP + 6 PPi + 3 SAH (1)where AA ¼ L-amino acid, HA ¼ D-hydroxycarboxylic acid,
SAM ¼ S-adenosyl-methionine, ATP ¼ adenosine triphosphate,
usually as a MgATP2 complex, COD ¼ cyclooligomer
depsipeptide, AMP ¼ adenosine monophosphate, PPi ¼ pyro-
phosphate, usually as a MgPPi
2 complex, SAH ¼ S-adeno-
sylhomocysteine.
The stoichiometry of the overall reaction in relation to the
requirement of 1 mole ATP per peptide or ester bond formed has
not been proven so far, but can be assumed based on analogous
studies in penicillin biosynthesis.85 The binding stoichiometry of
the required methylation cofactor could be determined as 1 mole
SAM per mole FeESYN.86 Reconstitution routinely involves
optimization of each of the substrate concentrations, with the
determination of apparent Km values. A complete kinetic
description of such complex systems has not been achieved yet.
The reaction cycle is considered irreversible, as COD hydrolysis
is not observed under normal conditions. However, as partial
reactions are indeed reversible (see below), byproducts such as
PPi and SAH act as inhibitors of enniatin synthesis. In this
context, Zocher and coworkers showed that SAH acts as a non-
competitive inhibitor with respect to the substrates L-Val, D-Hiv
and ATP.86 Upon omission of SAM, N-desmethyl enniatins are
obtained at about a ten-fold lower synthesis rate (kcat 0.13 s
1 for
enniatin, kcat 0.019 s
1 for desmethyl enniatin).79,86 Likewise,
limited SAM concentrations lead to the synthesis of partially
demethylated enniatin analogs.
The overall kinetic parameters of ESYN from Fusarium oxy-
sporum ETH 1536/9 were determined from double reciprocal
plots.86 The Km values of ATP, L-Val and D-Hiv were determined
to be 350 mM, 80 mM and 5 mM, respectively, and did not differ
significantly in the presence of SAH. The Km value of SAM was
measured to be 10 mM, which is in the range of other methyl-
transferases.87 At higher SAH concentrations, the synthesis of
desmethyl enniatins was suppressed, in contrast to a continued,
albeit decreased enniatin synthesis. This indicates that SAH only
has an effect on the rate of COD synthesis, but not on substrate
binding, and hence seems to interfere with elongation or product
cyclization. From these findings, it can be surmised that
suppression of desmethyl enniatin synthesis by SAH may have
a regulatory role on enniatin synthesis in vivo. This hypothesis is
supported by the finding that desmethyl enniatins are rarely
found in fermentation broths, while they are produced during
enniatin synthesis in vitro.86
COD formation can be detected by a colorimetric picrate assay
following extraction of mycelia, broth or assay mixtures,88 orThis journal is ª The Royal Society of Chemistry 2011quantified by radioactively labeled SAM or amino acids.84,86
COD analogs may be separated by TLC or HPLC.More recently
electrospray mass spectrometry (ESI-MS) combined with MS/
MS fragmentation has been established as an alternative and
more precise method for the detection and quantitation of
enniatins,89 as well as of PF1022-analogs.90
Using the enniatin synthetase as a model, the enzymatic
reconstitution of the 350 kDa PF1022 synthetase was also ach-
ieved, and PF1022 congeners were produced in vitro with the
substrates L-Leu, D-Lac, D-PheLac, Mg2+, SAM and ATP.61 The
Km values for product formation were determined to be Km(D-
Lac) ¼ 0.77  0.15 mM; Km(D-PheLac) ¼ 0.45  0.12 mM; and
Km(L-Leu)¼ 20 3 mM. In this in vitro approach, it was not only
possible to detect all of the naturally occurring PF1022 congeners
by mass spectrometry, but the rarely-occurring truncated hexa-
and tetradepsipeptides were also observed. The later compounds
were predicted to result from premature release from the PF1022
synthetase.3.3 Cloning of CODS genes
The first CODS gene cloned was the enniatin synthetase from
Fusarium scirpi ETH 1536/J5 (GenBank CAA79245).91 A cDNA
expression library constructed in phage lgt11 was screened with
a polyclonal antibody raised against ESYN from F. oxysporum
ETH 1536/9 and the identified gene fragment was used to probe
a genomic library. A 9393 bp intron-free reading frame was
confirmed by Northern hybridization. Identification of the
synthetase gene was accomplished indirectly, by disrupting the
corresponding enniatin synthetase gene in the plant pathogen F.
avenaceum by homologous recombination.53 A 1 kb fragment of
the F. scirpi CODS gene was cloned into a plasmid carrying the
hygromycin B phosphotransferase gene, and used to transform
F. avenaceum protoplasts. Nonproducer transformants were
further characterized and integrants identified which did not
transcribe or express the enniatin synthetase gene. Interestingly,
no single-copy transformant could be identified among the 19
nonproducers. The subcloned enniatin synthetase fragment of F.
avenaceum had only a single nucleotide difference compared to
the F. scirpi fragment used.
To clone the beauvericin and the bassianolide biosynthetic
genes from the hypocrealean entomopathogen Beauveria bassi-
ana ATCC 7159, Xu et al.22,57 designed several different pairs of
degenerate PCR primers against the conserved A3 and A8 motifs
of NRPSA domains.92 Some of these primers were heavily biased
towards the D-Hiv-activating A domains of the F. equiseti
enniatin synthetase (FeESYN).91 Enniatins, similar to beauver-
icin and bassianolide, contain D-Hiv as their 2-hydroxycarbox-
ylic acid constituents. Amongst the PCR products amplified
using B. bassiana total DNA as a template, two distinct ampli-
cons showed high sequence similarity to FeESYN. Fosmids from
a genomic DNA library of B. bassiana that hybridized to these
amplicons as probes were shown to derive from two disparate
genomic loci. Sequencing revealed that each of these loci encodes
one enniatin synthetase-like CODS. These CODSs were sepa-
rately knocked out, and several isolates of the strains with the
disrupted CODS genes, as well as ectopic integrants, were fer-
mented under beauvericin/bassianolide production conditions.
Ectopic integrants produced both beauvericin and bassianolideNat. Prod. Rep., 2011, 28, 99–124 | 105
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View Article Onlineat wild-type yields. Production of beauvericin was abrogated in
the BbBEAS knockout strains, while BbBSLS knockouts were
unable to produce bassianolide.22,57
The XsBSLS bassianolide synthetase of the wood-decaying
fungus Xylaria sp. BCC1067 was identified by a PCR-based
NRPS genome scanning strategy.55 One of the NRPS-encoding
amplicons was used as a probe to clone a CODS-encoding
genomic locus from a l phage genomic library. The nrpsxy gene
encoding this CODS was disrupted on the chromosome of
Xylaria sp. by directed gene knockout. Comparison of the
metabolic profiles of the mycelial extracts of the wild-type and
the mutant strains revealed the production of bassianolide in the
wild-type strain, and the abrogation of production of this COD
in the knockout strain.55 Prior to this work, bassianolide
production had not been described outside the hypocrealean
entomopathogens Beauveria and Verticillium.
The RsPFSYN PF1022 synthetase gene (BD013055) was
cloned from the unidentified fungus Mycelia sterilia.93 This
‘Fungus imperfectus’, classified later asRosellinia sp., was isolated
from the plant Camellia japonica in Japan.94
Two sequences of putative CODSs are also available from
GenBank, although the CODs that these synthetases produce
have not been experimentally established. ADB27871 is derived
from Fusarium oxysporum FB1501, a strain that produces both
beauvericin and the enniatins H, I and MK 1688.19 AAY73200 is
present in F. venenatum ATCC20334, a producer of enniatin B.95
Further genome mining has identified a putative CODS
(FOXG_11847) in F. oxysporum f. sp. lycopersici, a producer of
enniatins. The current gene model for this CODS ends prema-
turely at a contig gap, and therefore the encoded CODS is
a truncated protein with approximately 140 amino acids missing
from the C-terminus. Two additional putative CODS were also
found by genome mining from Trichoderma sp.:Fig. 1 Biosynthe
106 | Nat. Prod. Rep., 2011, 28, 99–124TRIVE1.E_GW1.16.170.1 from T. virens, and TRI-
AT1.E_GW1.1.2949.1 from T. atroviridae. To the best of our
knowledge, no COD has been isolated from either of these
Trichoderma species to date.4 Functional anatomy of fungal CODSs
4.1 Overall structures
The 10 known full-length (or close to full-length) CODS are
approximately 3150 amino acids in length and have a deduced
molecular weight of 350 kDa. They share 55–74% identity at
the protein level over their entire length. Interestingly, the two
CODS from Fusarium oxysporum, FolCODS from f. sp. lyco-
persici and FoCODS from strain FB1501, also share only 68%
identity.
All identified CODS, regardless of producing hexa- or octa-
depsipeptides, display the same extended bimodular architecture
with an identical domain arrangement: C1A1T1–C2A2M2T2aT2b–
C3 (Fig. 1). The only exception is the XsBSLS bassianolide
synthetase from Xylaria sp. which has an additional ‘‘reductase’’
domain attached at its C-terminus (see Section 5.1).
The A1 domain of the first module of the CODSs activates the
D-2-hydroxycarboxylic acid substrate and loads it onto the T1
domain in the same module, as shown experimentally in the case
of the loading of D-Hiv onto the enniatin synthetase.96,97 The A2
domain of the second module activates and loads an L-amino
acid substrate molecule onto each of the adjacent twin T2
domains. The second module also features an N-methyl-
transferase domain (M2) which is inserted into the A2 domain
between core motifs A8 and A9.86 The flexible loop between these
motifs often accommodates different editing domains in various
NRPSs.98,99 The SAM-dependent N-methyltransferase tailoringsis of CODs.
This journal is ª The Royal Society of Chemistry 2011
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View Article Onlinedomains of NRPSs82,86 modify the T domain-bound aminoacyl
thioesters prior to condensation by the adjacent C domain,100,101
and were first described and characterized from CODSs.82,86
Amide bond formation between the D-2-hydroxycarboxylic
acid and N-Me-amino acid thioesters is carried out by the C2
domain. NRPS C domains were shown to form several phylo-
genetic clades corresponding to functional subtypes.102 Although
the C2 domains of CODS catalyze a condensation between
substrates of D and an L configuration (i.e. they are formally DCL
domains), their core motifs are nevertheless more similar to
domains of the LCL subtype.
102 DCL condensation domains
evolved to perform a gating function to select upstream
substrates of the D configuration from the racemic mixtures
generated by the preceding E domains. CODS A1 domains
however specifically activate only the D enantiomer of the 2-
hydroxycarboxylic acid substrate,97 thus the C2 domains do not
have to select their substrates, nor do they have to interact with E
domains. Peptide bond formation between the two substrates
generates the dipeptidol monomer, three or four copies of which
would then be ligated and finally cyclized in a programmed
cyclooligomerization process to generate the cyclo-
hexadepsipeptide or cyclooctadepsipeptide products, respec-
tively.
This deduced assignment is based not only on the colinearity
rule of NRPS organization, but is also supported by both
limited proteolysis data and information from the expression of
CODS fragments.96,97 During the purification of the enniatin
synthetase from Fusarium scirpi, endogenous proteolysis was
observed, and two main fragments of 200 and 105 kDa were
purified.97 The 200 kDa fragment, comprising the C1A1T1C2
domains, catalyzed hydroxycarboxylic acid adenylation as well
as its attachment to the T domain as a thioester. A similar
fragment was also obtained from the F. sambucinum enniatin
synthetase. As the N-terminus was presumably blocked, the N-
terminal location of this fragment within the synthetase was
inferred from monoclonal antibody (mAb) binding.103 The
105 kDa fragment did not show catalytic activity, and was
mapped by mAb-binding and N-terminal sequencing to the
central region, comprising C2 and a segment of A2. Active site
radiolabeling of ESYN and its fragments with substrates,
followed by V8 protease digestion and HPLC separation,
identified fragments containing the A1T1 didomain for
hydroxycarboxylic acid attachment, and the M2T2aT2b domains
for amino acid attachment. Both types of fragments were also
shown to contain pantetheine as a required cofactor. Likewise,
the SAM-binding site has been localized by radiolabeling and
chymotryptic digestion to the M2-region.
97
The heterologous expression of various CODS fragments
comprising the regions C1A1T1 (121 kDa), A2M2T2aT2b
(158 kDa) and M2 (65 kDa) of the FeESYN ennitatin synthetase
has been achieved in E. coli.96 Catalytic activities of adenylate
formation have been demonstrated by D-Hiv and L-Val depen-
dent ATP-PPi-exchange. Activation of non-cognate substrates
was also detected, but this did not exceed 15 to 20% of that with
the cognate substrates. As misincorporation varied depending on
the fragment size for the A2-containing fragments, this promis-
cuity may be an artefact of improper folding. SAM binding by
the regions containing the M2 domain has also been validated by
photolabeling with 14C-SAM.This journal is ª The Royal Society of Chemistry 20114.2 Adenylation domains
The two adenylation domains activate their respective substrates
(D-hydroxycarboxylic acid [HA] for the A1 domain and L-amino
acid [AA] for the A2 domain) as acyl adenylate intermediates
(reactions (2a) and (2b)):
A1 + HA + ATP$ A1(HA–AMP) + PPi (2a)
A2 + AA + ATP$ A2(AA–AMP) + PPi (2b)
These activation reactions have been demonstrated by
substrate-dependent ATP–PPi exchange, relying on the reverse
reaction to generate labelled ATP from radiolabelled PPi and the
acyl adenylate intermediate.104
Structure-guided alignments of bacterial A domain sequences
can be used to predict the residues that line the substrate binding
pocket of these enzymes. The predicted amino acid residues can
then be used to predict the substrate specificity of the A domains
of novel bacterial NRPSs, relying on comparisons with a large
database of A domains with known substrate specificities.3,105,106
A 10-amino acid ‘‘specificity code’’ (the ‘‘non-ribosomal code’’) is
routinely used for these predictions.105 This non-ribosomal code
has recently been extended to a set of 34 amino acid residues,
modeled to lie within a distance of 8 A˚ around the substrate.107
In contrast to A domains in bacterial NRPS enzymes, an
a priori prediction of substrate specificity is currently not possible
in fungal NRPS A domains. The substrate specificity signature
motifs or ‘‘specificity codes’’ are divergent from those of bacteria,
and there is a relative lack of A domains with known substrate
specificities from fungal sources. Substrate predictions in CODS
are thus very imprecise, and even ‘‘postdictions’’ (deriving
consensus codes based on product structures) are somewhat
equivocal.4.2.1 Hydroxycarboxylic acid-activating domains (A1). The
A1 domains of the fungal CODSs all contain a Gly substitution
at the highly conserved Asp235 (GrsA numbering).105 This
Asp235 anchors the amino groups of amino acids, and its
replacement is a hallmark for A domains incorporating non-
amino acid precursors.99The 10-amino acids ‘‘codes’’ (Table 1) of
the CODS A1 domains are remarkably similar to each other, and
to the suggested D-Hiv consensus signature GALx(I/V)VG(S/
T)IK.22,57 The A1 signature of the RsPFSYN PF1022 synthetase
is also similar to the D-Hiv consensus. Although this domain
incorporates D-PheLac and D-Lac in vivo, it shows remarkably
relaxed substrate specificity in vitro.90 Interestingly, no similarity
is detected between the hydroxycarboxylic acid-activating A1
domain signatures of the fungal CODSs and the 2-ketocarbox-
ylic acid-activating A domain signatures derived from bacterial
depsipeptide NRPSs.22,57,108,1094.2.2 Amino acid activating domains (A2). The 10-amino acid
specificity codes of the A2 domains of CODSs show a higher
degree of variation (Table 2). A somewhat degenerate fungal Leu
signature was proposed57 that correctly identifies the Leu-specific
A2 domains of XsBSLS, RsPFSYN, and BbBSLS. It would
predict Leu specificity for the A2 domains of both CODSs from
Trichoderma sp., and for the A2 domain of FoCODS. However,Nat. Prod. Rep., 2011, 28, 99–124 | 107
Table 1 Specificity-conferring signatures of CODS hydroxycarboxylic acid adenylation domainsa
Synthetaseb Domain Specificityc 235d 236 239 278 299 301 322 330 331 517
Fungal D-Hiv signaturee
BbBEAS A1 D-Hiv
BbBSLS A1 D-Hiv
XsBSLS A1 D-Hiv
FeESYN A1 D-Hiv
FvCODS A1 ?
FolCODS A1 ?
FoCODS A1 ?
TaCODS A1 ?
TvCODS A1 ?
RsPFSYN A1 PheLac/Lac
a Amino acids identical to those in the proposed fungal A domain consensus signature are shown in white font on black background. Amino acids similar
(V ¼ I ¼ L; A ¼G, S ¼ T, W ¼ Y ¼ F) to those in the proposed A domain consensus signature are shown in bold type over a gray background. b NRPS
abbreviations: BbBEAS, Beauveria bassiana beauvericin synthetase;22 BbBSLS, B. bassiana bassianolide synthetase;57 FeESYN, Fusarium equiseti
enniatin synthetase;91 FoCODS, F. oxysporum cyclooligomer depsipeptide synthetase (ADB27871); FolCODS, F. oxysporum f. sp. lycopersici
cyclooligomer depsipeptide synthetase (FOXG_11847); FvCODS, F. venenatum cyclooligomer depsipeptide synthetase (AAY73200); RsPFSYN,
Rosellinia sp. PF1022 synthetase (BD013055); TaCODS, Trichoderma atroviridae cyclooligomer depsipeptide synthetase
(TRIAT1.E_GW1.1.2949.1); TvCODS, T. virens cyclooligomer depsipeptide synthetase (TRIVE1.E_GW1.16.170.1); XsBSLS, Xylaria sp.
bassianolide synthetase.55 c A domain specificities: D-Hiv, D-2-hydroxyisovalerate; PheLac/Lac, D-phenyllactate and D-lactate. d Amino acid
numbering according to the A domain of PheA.105,106 e Fungal D-Hiv signature as proposed previously.22
Table 2 Specificity-conferring signatures of CODS amino acid adenylation domainsa
Synthetaseb Domain Specificityc 235d 236 239 278 299 301 322 330 331 517
Fungal Leu signaturee
XsBSLS A2 Leu
RsPFSYN A2 Leu
TaCODS A2 ?
TvCODS A2 ?
BbBSLS A2 Leu
FoCODS A2 ?
BbBEAS A2 Phe
FeESYN A2 Val/Leu/Ile
FvCODS A2 ?
FolCODS A2 ?
FsESYN A2 Ile/Leu/Val
a Amino acids identical to those in the proposed fungal A domain consensus signature are shown in white font on a black background. Amino acids
similar (V ¼ I ¼ L; A ¼ G, S ¼ T, W ¼ Y ¼ F) to those in the proposed A domain consensus signature are shown in bold type over a gray
background. b FsESYN, Fusarium sambucinum enniatin synthetase;81 see Table 1 for further NRPS abbreviations. c A domain specificities: Val/Leu/
Ile, valine preferred, leucine and isoleucine also accepted; Ile/Leu/Val, isoleucine preferred, leucine and valine also accepted. d Amino acid
numbering according to the A domain of PheA105,106 e Fungal Leu signature, as proposed previously.57
108 | Nat. Prod. Rep., 2011, 28, 99–124 This journal is ª The Royal Society of Chemistry 2011
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View Article Onlinethe Phe-specific A2 domain of BbBEAS is also very similar to this
consensus sequence, leading to speculations of ‘‘keyhole
surgery’’-like mutations switching substrate specificity in closely
related A domains.4,6,22 The A2 signatures of the FeESYN and
FsESYN enniatin synthetases which incorporate branched chain
amino acids (including Leu) are more distantly related to the Leu
consensus sequence.
In a comparative analysis of purified enniatin synthetases from
Fusarium scirpi, F. sambucinum and F. lateritium, amino acid
specificities were analyzed by estimation of catalytic constants
from product formation.81 The most efficient synthesis was
found with L-Val for the F. scirpi enzyme, L-Ile and L-Leu for the
F. sambucinum enzyme, and L-Val for the F. lateritium enzyme.
These trends are exactly what one would expect from the
compositions of the enniatin congener mixtures produced by
these strains in vivo.4.3 Carrier domains
Transfer of acyl adenylates (reactions (3a) and (3b)) to the 40-
phosphopantetheine cofactor (Sp) attached to the cognate carrier
domains (termed T1 and T2a and/or T2b) has been shown by the
isolation of acid stable thiol intermediates, concomitantly
demonstrating the presence of N-methyl-aminoacyl thioesters
preceeding ester bond formation:
A1(HA–AMP) + T1SH
p1/ T1–S
p1–HA + AMP + A1 (3a)
A2(AA–AMP) + T2SH
p2/ T2–S
p2–AA + AMP + A2 (3b)
Comparison of the T1 and twin T2 carrier domains show
a relatively high primary sequence divergence. Both T2 domains
might interact with the adjacent N-methyl-transferase domain to
facilitate N-methylation of the amino acid intermediate (reaction
(4)). The twin T2 domains contain more highly conserved
charged residues than the T1 domains, presumably to facilitate
multiple docking events with the A, M and C domains, assuming
that the primary docking events of these domains rely on elec-
trostatic interactions. In one model proposed for cyclo-
oligomerization in fungal CODS (see below), only the T2a
domain anchors the amino acid and its N-methyl intermediate,
while the T2b domain serves as a ‘‘waiting position’’ that holds the
resulting dipeptidol intermediate while this awaits cyclo-
oligomerization.110 This scheme implies a lack of interaction
between T2b and A2 and M2.4.4 Methyltransferase domains (M2)
The aminoacyl thioester intermediate is N-methylated upon
interaction of the T2 carrier domain with the methyltransferase
domain M2 (reaction (4)), which is integrated between motifs A8
and A9 in the adenylation domain A2.
T2–S
p2–AA + SAM/ T2–S
p2NMeAA + SAH (4)
It is presently unknown if both of the twin carrier domains, or
only the closely associated T2a domain interact with the M2
domain. The M2 domain of the enniatin synthetase from Fusa-
rium scirpi has been mapped by both protein chemical methods
and fragment expression. The 49 kDa protein has been expressedThis journal is ª The Royal Society of Chemistry 2011in Saccharomyces cerevisiae with an N-terminal hexahistidine tag
and a C-terminal streptavidin II fusion peptide.100 Contacts with
the substrate SAM have been assigned by saturation transfer
difference (STD) NMR spectroscopy. Catalytic activity has been
demonstrated with L-aminoacyl-N-acetylcysteamine thioesters
(aminoacyl-SNACs) of substrate-related amino acids. Km values
of L-Val-SNAC and SAM were similar for enniatin synthetase
and the expressed fragment, thus indicating correct folding.
In an analysis of methyltransferase domains of multifunctional
PKS and NRPS systems of both bacterial and fungal origin,
Ansari et al.111 have shown that N-, O-and C-methyltransferase
sequences from distinct subgroups. Structure-guided sequence
alignments led to the identification of structural motifs in M2
domains that are similar to those in non-integrated methyl
transferases.1124.5 Condensation domains (C)
The carrier domains loaded with thioesters of the hydrox-
ycarboxylic acid and the N-methyl amino acid, respectively, will
then interact with the condensation domain C2 to form the
dipeptidol intermediate HA-NMeAA, which remains bound to
the acceptor thiolation domain T2 (reaction (5)):
T1–S
p1–HA + T2–S
p2–NMeAA/
T1–SH
p1 + T2–S
p2–NMeAA–HA (5)
The isolation of the dipeptidol reaction intermediate shows
that the peptide bond is formed first,84 followed later by the ester
bond-forming condensation and cyclization reactions. The
production of the diketomorpholine bassiatin (9) from the
beauvericin producer Beauveria bassiana, and the isolation of
cyclo(Lac-MeLeu) and cyclo(PheLac-N-Me-Leu) from the
PF1022-producerRosellinia sp. (W.Weckwerth,Doctoral Thesis,
TU Berlin, 1998) indicate that some dipeptidols may undergo an
early cyclization reaction, instead of being used for cyclo-
oligomerization. Indeed, such side products show bioactivity,72
and their formation could be considered as a potential example
of multiple product formation from a single NRPS.
The details and the sequence of the cyclooligomerization
reactions that follow the formation of the first dipeptidol and
finally lead to the release of the finalized COD product remain to
be demonstrated. Both the twin T2 domains and the N- and C-
terminal C domains of CODS were proposed to take part in
cyclooligomerization, as described in Section 4.6. The N-
terminal C1 and the C-terminal C3 domains of fungal CODSs
show overall sequence similarity to condensation domains, but
their core motifs show substantial variation from the canonical
forms.22,57,99 C3 domains are more conserved, with highly
recognizable core motifs C2–C5. The core motif C3 that contains
the canonical His active site (HHxxDG) is only slightly altered to
SHALYDG, and is apparently invariant in all the C3 domains of
CODSs. The C3 domains show the highest similarity (42%
identity) to the C-terminal C domains of the aureobasidin A1
synthetase from Aureobasidium pullulans (ACJ04424) and the
cyclosporine synthetase of Tolypocladium inflatum (CAA82227).
These C-terminal C domains are predicted to catalyze macro-
cyclization by ester (aureobasidin synthetase) or peptide bond
formation (cyclosporine).114,115 On the other hand, the C3Nat. Prod. Rep., 2011, 28, 99–124 | 109
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View Article Onlinedomains of CODS exhibit very low similarity to the C-terminal C
domains of those bacterial NRPSs which catalyze macro-
cyclization by ester bond formation during rapamycin, FK506,
FK520 and meridamycin biosynthesis, and display negligible
similarity to bacterial TE domains that catalyze cyclo-
oligomerization during enterobactin, bacillibactin, valinomycin
and cereulide synthesis. The C1 domains of CODSs are more
divergent, with only a variant of the core motif C3 (SHxxVD)
recognizable. The BbBEAS and the TaCODS C1 domain active
site signatures (HLxxxD and SYxxVD, respectively) even lack
the His residue which is considered to be essential for conden-
sation reactions.22,113 The C1 domains show no close similarity to
any particular group of C domains outside CODSs. The diver-
gence of the C1 and C3 domains of CODSs from the canonical
amide bond-forming C domains of other NRPSs might be
a consequence of their suggested role in the cyclooligomerization
process, including the recursive ester bond-forming ligations and
the product-releasing cyclization reaction. However, there is no
experimental evidence to support the hypothetical functions of
either the C1 or C3 domains in cyclodepsipeptide synthesis to
date.4.6 Iterative and recursive processes during cylooligomerisation
One of the most interesting processes during COD biosynthesis is
the oligomerization and cyclization of the peptidol monomer
products on the CODS. According to the classical ‘‘parallel
model’’ (Figs. 1 and 2), formulated for enniatin biosynthesis by
the Zocher group91,110 and adapted for all fungal CODSs, the
dipeptidol monomer formed from the condensation of the 2-
hydroxycarboxylic acid and the N-Me-amino acid will remain
bound on the T2a domain. The dipeptidol intermediate may then
be transferred from carrier domain T2a to T2b, with the latter
serving as a dedicated ‘‘waiting position’’ only. Alternatively, theFig. 2 Models for COD biosynthesis via stepwise assembly (Linear
model) or oligomerization (Parallel model). Dark grey spheres represent
2-hydroxycarboxylic acid moieties; light grey spheres symbolize amino
acid moieties. See text for details.
110 | Nat. Prod. Rep., 2011, 28, 99–124T2b domain might be available for the sequential assembly of
a second peptidol intermediate: in this scenario the T2a and T2b
domains would be functionally equivalent, and the ‘‘waiting
position’’ would result from the dynamics of the process. Either
way, the twin domains T2a and T2b, each loaded with a dipepti-
dol, were proposed to be involved in the formation of a tetra-
peptidol by dimerization (Fig. 2). The formation of this
tetrapeptidol may be catalyzed by the condensation domain(s)
C3 and/or C1 (reaction (6)), and this intermediate remains
attached to either T2a or T2b:
T2a–S
p2–NMeAA–HA + T2b–S
p3–NMeAA–HA/
T2a–SH
p2 + T2b–S
p3–[NMeAA–HA]2 (6)
Early release of the enzyme-bound tetrapeptidols in the form
of cyclic tetradepsipeptide products was observed in vitro in
PF1022 synthesis (W. Weckwerth, Doctoral Thesis, TU Berlin,
1998). The same truncated compounds with the structures
cyclo(D-Lac–N-Me-L-Leu–D-Lac–N-Me-L-Leu), cyclo(D-Lac–N-
Me-L-Leu–D-PheLac–N-Me-L-Leu), and cyclo(D-PheLac–N-Me-
L-Leu–D-PheLac–N-Me-L-Leu) were also found to be formed
during fermentation of the wild-type producer strain.
After the tetrapeptidol stage, repetition of reactions (2)–(5)
leads to a synthetase with a dipeptidol intermediate anchored at
one of the T2 domains, which could be ligated by the C1 and/or
the C3 domains with the tetrapeptidol intermediate parked on the
other T2 domain. This leads to the formation of the hexapeptidol
intermediate (reaction (7a)).
T2a–S
p2–NMeAA–HA + T2b–S
p3–[NMeAA–HA]2/
T2a–SH
p2 + T2b–S
p3–[NMeAA–HA]3 (7a)
In case of octapeptidols such as PF1022, a further dipeptidol
assembly and ligation cycle is envisioned. After the appropriate
number of recursive intermolecular ligations (n ¼ 3 for cyclo-
hexadepsipeptides and n ¼ 4 for cyclooctadepsipeptides), the
linear oligomer might fold back and become a substrate for the
intramolecular cyclization that releases the final cyclooligomer
product (equation (7b)). This product release reaction is analo-
gous to that catalyzed by cyclizing C or TE domains, and has
been proposed to be carried out by one or both of the C1 and the
C3 domains.
91,110
T2b–S
p3–[NMeAA–HA]n/ T2b–SH
p3 + COD (7b)
An alternative mechanism to the classic ‘‘parallel’’ model of
cyclooligomerization would involve the buildup of cyclooligomer
depsipeptides on the enzyme by stepwise iterative condensations
(Fig. 2). During this ‘‘linear’’ mechanism, dipeptidol formation
on the T2 domains would be followed by condensation with D-
Hiv presented on the T1 domain, catalyzed by either or both the
C1 or C3 domains, leading to a tripeptidol. The tripeptidol would
then be condensed with the N-Me-amino acid on the T2 domain
to form the tetrapeptidol. The process would continue in a step-
wise manner until the appropriate chain length is achieved and
synthesis is terminated by cyclization as catalyzed by either or
both of the C1 or C3 domains. In this model, the presence of the
two copies of the T2 domains would not be a structuralThis journal is ª The Royal Society of Chemistry 2011
Fig. 3 Phylogenomic analysis of CODSs. The sequences of the C1, C2,
and C3 domains of the CODSs were concatenated, a multiple sequence
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View Article Onlinerequirement of COD biosynthesis, and might only increase the
turnover of the enzyme, a mechanism which has a precedent in
polyunsaturated fatty acid biosynthesis.116,117
Experimental evidence for the ‘‘parallel’’ model is limited at the
moment, and does not conclusively rule out the ‘‘linear’’ mech-
anism. The enniatin synthetase was shown to be a monomer,110
and thus the active sites on a single synthetase should be suffi-
cient for the formation of a COD, excluding the possibility that
three synthetase subunits would each contribute one dipeptidol
to the final product. Performic acid release of products after
a brief in vitro condensation reaction with the purified FeESYN
enniatin synthetase yielded only the dipeptidol and the tetra-
peptidol,84 supporting the ‘‘parallel’’ mechanism. However,
product yield in these pioneering experiments was extremely low.
Therefore the formation of tri- and/or pentapeptidols might have
gone undetected if synthesis of these species was rate limiting
compared with their condensation with amino acids to yield the
tetra- and hexapeptidols. Further evidence for the ‘‘parallel’’
mechanism comes from mass spectra of the products of PF1022
fermentations, in which only the even-numbered truncated
products (diketomorpholines, tetra- and hexadepsipeptides)
could be detected.61 Further investigations by CODS domain
engineering, and Fourier-transform mass spectrometric detec-
tion and identification of the enzyme-bound intermediates
promises to shed more light on this interesting process.118,119
alignment was created in VectorNTI, and bootstrapped trees were
calculated in ClustalX with the neighbor-joining method using 1000
repeats. The phylogram was plotted with NJPlot using C1C2C10_Aur,
the concatenated sequences of the C1, C2 and C10 domains of the aur-
eobasidin synthetase,114 as the outgroup. The scale shows the number of
substitutions per site, and significant (>500) bootstrap values are indi-
cated near the forks. (3) and (4) indicates the cyclotrimeric or cyclo-
tetrameric nature of the known COD products, respectively.4.7 Cyclooligomerization and the phylogeny of CODSs
Fungal CODSs are programmed to utilize three (hexadepsipep-
tides) or four (octadepsipeptides) of the dipeptidol monomers
during cyclooligomerization. The strict control of the number of
monomer ligations catalyzed by these enzymes might thus be
expected to be reflected in an appropriate clading of the CODSs,
especially their C domains, during multiple sequence alignments.
However, this is not the case: alignments with full-size CODS, or
their individual C domains, fail to reveal clustering according to
the oligomerization state, or even product structure (Fig. 3).
Thus, the trimerizing BbBEAS beauvericin synthetase, and the
tetramer-forming BbBSLS bassianolide synthetase form a clade
that is a sister of a clade containing all the CODS from Fusarium
spp. These sister clades branch from another clade containing
sequences from Xylariaceae (XsBSLS and RsPFSYN) and from
Trichoderma. The small number of CODS sequences, and the
uncertainty as to the products of the Trichoderma and some of
the Fusarium CODSs, does not currently allow us to discern the
underlying evolutionary history of these enzymes, and we also
cannot correlate oligomerization state with sequence motifs.
Programming of the product chain length of other iterative
enzymes (for example the fungal polyketide synthases, bacterial
Type II polyketide synthases, and the chalcone synthase-like
Type III polyketide synthases) also cannot reliably be predicted
from primary amino acid sequences, in spite of recent progress.120
The number of ligations during cyclooligomerization (i.e.
product oligomerization state) is thus probably determined by
the shape and size of the reaction chamber within the CODSs,
and might be modulable by a small number of mutations that can
transform a CODS from a trimer-forming to a tetramer-forming
enzyme (or vice versa) after gene duplication and drift.This journal is ª The Royal Society of Chemistry 20114.8 Cyclooligomerization during fungal and bacterial COD
biosynthesis
Similar to fungal CODs, bacterial cyclooligomer peptides (e.g.,
gramicidin S) and depsipeptides (e.g., enterobactin, valinomycin,
cereulide, and chromodepsipeptides) are also biosynthesized by
Type B iterative NRPSs. While the bacterial synthetases also
have modules that are responsible for the programmed iterative
synthesis of the peptide/peptidol monomer units, their cyclo-
oligomerization mechanisms involve different domains
compared to those in the fungal CODSs (Fig. 4). Bacterial
cyclooligomerizing synthetases do not have N- and C-terminal C
domains, or twin T domains in their second module. Instead,
these enzymes feature a recursive TE domain, located at their C-
terminus. In the example of the enterobactin synthetase, this TE
holds the first monomer unit as an acyl-O-TE ester intermediate
on its active site Ser, until the next monomer unit is assembled on
the adjacent T domain. The recursive TE domain then ligates two
monomers to form a dimer that can be released by TE-catalyzed
cyclization, or might serve as a partner for further oligomeriza-
tions and the cyclization (Fig. 4).8,118,121–123 Excised recursive TE
domains from the gramicidin S and the thiocoraline synthetases
have been shown to catalyze cyclodimerization in vitro.124,125
Considering the radically different enzymology of the bacterial
vs. the fungal cyclooligomerizing synthetases, recursive ligation
and cyclization catalysis during COD biosynthesis must haveNat. Prod. Rep., 2011, 28, 99–124 | 111
Fig. 4 Cyclooligomerization during COD biosynthesis in bacteria vs. fungi. See text for details.
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View Article Onlinea polyphyletic origin and have developed through convergent
evolution.4.9 Pseudo-cyclodimeric fungal natural products
Fungal cyclodepsipeptides showing a pseudo-cyclodimeric
structure have been isolated from several Dothiodeomycete
Pithomyces spp. (teleomorph: Leptosphaerulina spp.). Thus, the
cyclotetradepsipeptide angolide (5)12 and the cyclo-
hexadepsipeptide sporidesmolide (6)13 are apparent dimers of
a dipeptidol (angolide) or tripeptidol (sporidesmolide). However,
the two ‘‘monomers’’ are not strictly equivalent: one of these
units contains D and L amino acids, while the other features
exclusively L amino acids. Two hypotheses have been advanced
to explain this non-equivalence of the two halves of these
molecules. For angolide, a cyclic, all-L dipeptide intermediate,
possibly a diketopiperazine, was proposed to undergo random
enzyme-catalyzed inversion of the a-position of one residue only,
followed by N-acylation and insertion of the two L-Hiv residues,
respectively.126 An alternative mechanism was also suggested for
sporidesmolide and for angolide involving the biosynthesis of
two depsipeptidols on two nonequivalent ‘‘sites’’ of a multien-
zyme, followed by cyclodimerization and multienzyme-
controlled specific isomerization.126,127 We propose that the
simplest biosynthetic model for these compounds would involveFig. 5 Proposed biosynthesis of angolide, a pseudo-cyclodimeric fungal na
starter unit. The picture shows the growing depsipeptide chain as the approp
112 | Nat. Prod. Rep., 2011, 28, 99–124a four-module (angolide) or six-module (sporidesmolide) type A
(processive) NRPS (Fig. 5). The presence of epimerization
domains in the modules for D amino acids would account for the
incorporation of L amino acid precursors into all amino acid
positions, with a cyclizing (but not cyclooligomerizing) C-
terminal TE or C domain releasing the cyclic product from the
enzyme. Confirmation of this hypothesis awaits sequencing of
the respective gene clusters.5 Precursor supply, regulation and export
5.1 Biosynthesis of 2-hydroxycarboxylic acids in COD-
producing fungi
Fungi biosynthesize the D-2-hydroxycarboxylic acid constituents
of their CODs by reducing the appropriate free ketocarboxylic
acids, derived from amino acid metabolism. COD biosynthesis
seems to have recruited enzymes and their encoding genes from
two distinct superfamilies for this purpose. Thus, beauvericin
biosynthesis in Beauveria bassiana, enniatins biosynthesis in
Fusarium spp., and bassianolide biosynthesis inXylaria sp. utilize
ketoisovalerate reductases of the 6-phosphogluconate dehydro-
genase superfamily to produce D-Hiv. In contrast, PF1022
biosynthesis in Rosellinia, and the biosynthesis of the unknown
CODS of Trichoderma virens and T. atroviridae seems to havetural product. One of the D-Hiv moieties was arbitrarily assigned as the
riate intermediates anchored on the T domains. See text for details.
This journal is ª The Royal Society of Chemistry 2011
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View Article Onlineco-opted dehydrogenases from the D-isomer-specific 2-hydroxy-
acid dehydrogenase superfamily.
The Zocher lab described the purification and enzymatic
characterization of a 53 kDa ‘‘D-hydroxyisovalerate dehydroge-
nase’’ from Fusarium sambucinum.128–130 This enzyme was shown
to catalyze the reversible interconversion of ketoisovalerate and
D-Hiv, with high enantioselectivity in an ordered bi-bi kinetic
mechanism. The sequential order of the reaction was found to be
identical to that of ketopantoate reductases from the 6-phos-
phogluconate dehydrogenase superfamily. Ketopantoate reduc-
tases (E.C. 1.1.1.169) catalyze the NADPH-dependent
stereospecific reduction of ketopantoate to D-pantoate in vitamin
B5 biosynthesis.
131 The F. sambucinum D-Hiv dehydrogenase
displayed high substrate specificity, and was specific for NADP+.
However, the sequence of the protein and its encoding gene have
not been reported.
The BbBEAS beauvericin synthetase locus of Beauveria
bassiana was found to contain a gene (kivr) encoding a putative
protein with a GxGxxGxxxA NAD(P)H-binding signature and
high similarity to COG1893 ketopantoate reductases.132 The
predicted KIVR protein had a deduced MW ¼ 51 493 Da, in
good agreement with the size of the Fusarium sambucinum D-Hiv
dehydrogenase enzyme. KIVR was predicted to show a similar
secondary structure to those of ketopantoate reductases. It was
also predicted to share a Glu-Asn-Lys active site triad archi-
tecture with them, as well as key conserved amino acids
involved in substrate and product orientation. No similar gene
was clustered with the BbBSLS bassianolide synthetase of the
same strain. KIVR was expected to supply D-Hiv for the
biosynthesis of beauvericin and perhaps bassianolide: accord-
ingly, disruption of the kivr gene in the genome of B. bassiana
abrogated not only the production of beauvericin, but also that
of bassianolide. Chemical complementation of the mutant by
supplementing the fermentation medium with D-Hiv restored
the production of both CODs. Thus, KIVR is the only enzyme
that can produce D-Hiv in B. bassiana for the biosynthesis of
both beauvericin and bassianolide, thereby representing a func-
tional crosstalk between the two COD biosynthetic systems of
the strain.132
Immediately upstream of the FolESYN enniatin synthetase of
Fusarium oxysporum f. sp. lycopersici is a divergently transcribed
gene (FOXG_11846) that encodes a putative ketoisovalerate
reductase which is 61% identical and 76% similar to the B.
bassiana KIVR. The respective predicted protein
FOXG_11846.2 was erroneously annotated in a C-terminally
truncated form, but this shortened version of 367 amino acids
was successfully expressed in E. coli, although mostly in the form
of inclusion bodies (P. Grzesik, Diploma Thesis, TU Berlin,
2009). The N-terminally His-tagged construct of about 43 kDa
showed KIV-dependent NADPH-consumption with a Km of
2.5 mM, compared to 0.2 mM for the 53 kDa dehydrogenase
isolated from F. sambucinum.
The uncharacterized reductase domain appended to the C-
terminus of the XsBSLS bassianolide synthetase of Xylaria sp.
(amino acids 3136–3546) also shows 25% identity and 43%
similarity to KIVR. Both FOXG_11846 and the R domain of
XsBSLS retain the NADP+-binding site and the Glu-Asn-Lys
active site triad architecture of the B. bassiana KIVR and the
related ketopantoate reductases from the 6-phosphogluconateThis journal is ª The Royal Society of Chemistry 2011dehydrogenase superfamily, and likely supply D-Hiv or similar D-
2-hydroxycarboxylic acids for their cognate CODS partners.
In contrast, the putative keto(phenyl)propionate reductase
BD105415 which is clustered with the RsPFSYN ofRosellinia sp.
displays a very low (10%) identity to the KIVR proteins. The
Glu-Asn-Lys active-site triad of the KIVR sequences or the
ketopantoate reductases from the 6-phosphogluconate dehy-
drogenase superfamily are not retained in BD105415, nor are the
additional residues involved in the stabilization of the substrate
or the product. Instead, BD105415 reveals significant similarity
to lactate dehydrogenases (COG1052) within the D-isomer-
specific 2-hydroxyacid dehydrogenase superfamily, with an
NAD(P)+-binding Rossmann fold (cl09931) at the C-terminal
half of the protein. Similarly, the Trichoderma CODSs are also
clustered with putative NAD(P)+-binding, D-isomer-specific
2-hydroxyacid dehydrogenases (T. virens: e_gw1.82.328.1,
T. atroviridae: fgenesh1_pm.contig_27_#_418 and Tri-
at1.e_gw1.1.3874.1). Interestingly, while the T. virens
e_gw1.82.328.1 dehydrogenase and the T. atroviridae Tri-
at1.e_gw1.1.3874.1 enzymes are 86% identical at the protein
level, the two T. atroviridae dehydrogenase protein sequences,
both bordering the same CODS, share only 24% identity.
Biosynthesis-guided purification studies in the PF1022
producer led to the purification of a 38 kDa D-phenyllactate
dehydrogenase (W. Weckwerth, Doctoral Thesis, TU Berlin,
1998). In these studies, the phenylpyruvate dependence of COD
biosynthesis was monitored in a reconstituted reaction system
containing the PF1022 synthetase, Leu, ATP, SAM, and
NADPH. The D-phenyllactate dehydrogenase enzyme was
purified about 5000-fold in 7 steps, and shown to reduce phe-
nylpyruvate with a Km ¼ 38 mM. Besides phenylpyruvate, p-
hydroxyphenyl-pyruvate (Km ¼ 45 mM) and 2-ketoisocaproate
(Km ¼ 53 mM) were also accepted as substrates. Results from gel
filtration experiments indicated a dimeric structure. Internal
tryptic peptides of the purified enzyme showed some similarity to
BD105415 (predicted size 36 470 Da).5.2 Hydroxycarboxylic acid incorporation in bacterial vs.
fungal NRPS systems
Incorporation of intra-chain 2-hydroxycarboxylic acids into
bacterial cyclodepsipeptide products (e.g., kutznerides, valino-
mycin, cereulide, hectochlorin and cryptophycin) was shown to
proceed by a mechanism different from that in COD-bio-
synthesizing fungi.98,108,109,133 Instead of utilizing preformed 2-
hydroxycarboxylic acids as substrates, the respective bacterial
NRPS A domains activate and load the corresponding 2-keto-
carboxylic acids onto the multienzymes. Here, the ketocarboxylic
acyl-thioesters undergo stereospecific reduction in cis by
a ketoreductase (KR) domain, yielding the D- or L-hydroxy-
carboxylic acyl-thioesters ready for condensation. The on-
demand production of hydroxycarboxylic acids in bacteria, and
the biosynthesis of a free pool of hydroxycarboxylic acids in
fungi both rely on the readily available ketocarboxylic acid pool,
derived from amino acid catabolism and anabolism. However,
these different hydroxycarboxylic acid supply routes still
conceivably represent another example of convergent evolution
for the generation of a chiral precursor for natural product
biosynthesis in bacteria vs. fungi.Nat. Prod. Rep., 2011, 28, 99–124 | 113
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View Article Online5.3 Regulation and export
While most of the genes in the immediate genomic neighborhood
of the identified CODS encode hypothetical proteins with no
predicted functions, some genes code for predicted proteins with
potential functions in the transcriptional regulation of the
synthetase, or in the export of the produced COD. However,
there is no direct proof for the involvement of any of these pre-
dicted proteins in COD biosynthesis.
Genes encoding putative regulatory proteins containing the
Gal4-like Zn2Cys6 binuclear cluster DNA-binding domain
(Smart SM00066, InterPro IPR001138) were found to be clus-
tered with BbBEAS (orf1),22 and FolCODS (FOXG_11849 and
FOXG_11859). The BbBSLS bassianolide synthetase cluster also
encodes a putative Gal4-like transcriptional regulator (ORF5)
and the predicted GTPases ORFs 1 and 4.57 A predicted Gal4-
like transcription factor (gw1.82.211.1) is adjacent to the
T. virens CODS, while the T. atroviridae CODS is clustered
with a putative TFIIS-type zinc finger transcription factor
(Triat1.e_gw1.1.2849.1).
The nrpsxy gene encoding the XsBSLS bassianolide synthetase
of Xylaria sp. was found to be clustered with the efxy gene
encoding a putative major facilitator superfamily (MFS) trans-
porter with significant similarity to other MFS transporters
encoded in many fungal genomes.55 The two Trichoderma
CODSs are also clustered with hypothetical MFS transporters
(T. virens: fgenesh1_pg.82_#_180; T. atroviridae: Tri-
at1.e_gw1.1.3461.1). The Fusarium oxysporum f. sp. lycopersici
FolCODS is clustered with FOXG_11845 which encodes a pre-
dicted ATP binding cassette (ABC) multidrug transporter. No
transport-related putative proteins were found to be encoded in
the sequenced regions of the beauvericin or the bassianolide
clusters of Beauveria bassiana.22,57
6 Heterologous expression of CODSs
6.1 Enniatin synthetase gene fragments
Heterologous expression of sub-fragments of FeESYN was
achieved by Zocher and coworkers, aiming at high expression
yields for subsequent biochemical characterizations. The first
module (the ‘‘EA fragment’’), including the C1A1T1 domains,
and the second module (the ‘‘EB fragment’’), including the
A2M2T2aT2b-and a truncated C3 domain, were separately cloned
into the E. coli vectors pBluescript SK+ and pUC8. Expression
levels of the ESYN fragments cloned into the pBluescript vector
reached 20–40% of the total cellular protein, compared to the
pUC8 constructs which yielded 10–20% recombinant protein.
Starting from the EB fragment-encoding gene fragment, several
truncated constructs (e.g. A2, A2M2, M2) were also made.
96
Unfortunately, mostly insoluble proteins were obtained that
needed to be denaturated and refolded, significantly increasing
the experimental efforts for obtaining functional proteins. The
activities of both adenylation domains of FeESYN (A1 and A2)
were characterized using the ATP-PPi exchange reaction.
104
However, further assays that measure the covalent loading of the
substrates (D-Hiv and L-Val) on the T domains of the expressed
protein fragments as hydroxyacyl or aminoacyl thioesters were
unsuccessful. This suggested that the phosphopantetheinyl
transferase of the E. coli fatty acid synthase does not recognize114 | Nat. Prod. Rep., 2011, 28, 99–124the FeESYN as its substrate.22 The truncated constructs were
also tested for methyltransferase activity, and UV-induced
photoaffinity labeling134 with [14C]- or [3H]-SAM has also been
performed in order to prove specific covalent binding of this
cosubstrate to the M2 domain.
96 Truncated fragments of the
FeESYN containing the M2 domain could be photolabeled,
whereas fragments without the predicted M2 domain were not.
Another interesting outcome of the experiments was that
a truncated protein composed of the N-terminal subdomain of
A2 withM2 was not able to activate the substrate L-Val. Thus, the
activation is based on both of the N- and C-terminal subdomains
of the adenylation domain.135 In subsequent studies several
deletion constructs encoding segments of the M2 domain were
generated, and the expressed recombinant proteins were tested
by radiolabeling with SAM. These studies addressed the role in
cofactor binding of the four conserved motifs of methyl-
transferases (I: VLEIGTGSGMIL; II: SYVGLDPS; IV:
DLVVFNSVVQYFTPPEYL and V: ATNGHFLAARA).101 A
deletion of 11 amino acids from the N-terminus led to a decrease
in the cofactor binding, but surprisingly, M2 fragments with a 21-
amino acid N-terminal deletion displayed an even higher binding
activity than the embedded M2-domain in the wild-type FeE-
SYN. Although the conserved motifs are closer to the N-
terminus (whole protein: 558 amino acids, start of motif I: 44 aa;
motif II: 91 aa; motif IV: 138 aa and motif V: 180 aa from the N-
terminus), the truncation of the C-terminal part led to a more
significant decrease of the SAM binding of the enzyme.101
Since the attempts to obtain soluble single domains of the
FeESYN in E. coli were not successful, the M2 methyltransferase
domain was overexpressed in yeast, yielding the desired protein
in soluble fraction. The M2 domain (1.3 kbp) was cloned in the
E. coli–S. cerevisiae shuttle vector pYEXTHS-BN with an N-
terminal His6-tag and C-terminal strep II fusion peptide.
Cofactor binding was demonstrated by photoaffinity labeling134
and by saturation transfer difference (STD)-NMR spectroscopy
under equilibrium conditions, establishing the distance and
orientation of enzyme-bound SAM relative to the binding site.
The kinetic constants for binding of the cofactor and the
substrate were also determined, and were shown to be similar to
those of the M2 domain embedded in FeESYN, indicating that
the dissected domain was correctly folded upon heterologous
expression. The specificity of the methyltransferase was investi-
gated using N-acetylcysteamine thioesters (SNAC) of L-Leu, L-
Ile, L-Phe, L-Val and D-Val. Surprisingly, all tested amino acids
except D-valine yielded methylated products at similar rates, as
detected by radioactive labeling and MALDI-TOF mass spec-
trometry. Although the M2 domain accepts only amino acids
with an L-configuration, it apparently has a widened substrate
tolerance, even for substrates which had previously been shown
not to be substrates for the full-length enniatin synthetase, such
as L-Phe.1006.2 Heterologous production of beauvericin
The BbBEAS beauvericin synthetase of Beauveria bassiana has
been functionally expressed in E. coli using the expression vector
pACYCDuet-1 (Novagen).22 The Duet system allows the cloning
of two ORFs behind two separate T7 promoters for co-expres-
sion from the same vector: Xu et al.22 used this feature toThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlineco-express bbBeas with the broad-spectrum phosphopante-
theinyl transferase sfp gene from Bacillus subtilis136 to guarantee
the production of holo-BbBEAS. E. coli BL21 (DE3) carrying
the expression construct produced small amounts of beauvericin
upon supplementation of the cultures with D-Hiv. Heterologous
production of beauvericin was improved by using Origami
B(DE3) as the expression host: this strain facilitates protein
folding by promoting cytoplasmic disulfide bond formation.
Reduction of the cultivation temperature to 16 C during protein
expression, and feeding both D-Hiv and L-Phe during the beau-
vericin production stage led to a process with a beauvericin yield
of approximately 8 mg/L in E. coli. This represents approxi-
mately 40% of the yield of the native producer B. bassiana, and
a reduction in fermentation times. Importantly, beauvericin fromTable 3 Naturally occurring enniatin congeners
Enniatin R1 R2 R3 R4 R5 R6 M
A iPr iPr iPr sBu sBu sBu M
A1 iPr iPr iPr iPr sBu sBu M
B iPr iPr iPr iPr iPr iPr M
B1 iPr iPr iPr sBu iPr iPr M
B2 iPr iPr iPr iPr iPr iPr H
B3 iPr iPr iPr iPr iPr iPr H
C iPr iPr iPr iBu iBu iBu M
D (¼ B4) iPr iPr iPr iBu iPr iPr M
Ea iPr iPr iPr iBu iPr sBu M
iPr iPr iPr iBu sBu iPr
F iPr iPr iPr iBu sBu sBu M
G iPr iPr iPr iPr iBu iBu M
H sBu iPr iPr iPr iPr iPr M
I sBu sBu iPr iPr iPr iPr M
MK 1688 sBu sBu sBu iPr iPr iPr M
J1 iPr iPr iPr Me iPr iPr M
J2 iPr iPr iPr iPr sBu Me M
J3 iPr iPr iPr iPr Me sBu M
K1 iPr iPr iPr Et iPr iPr M
L iPr iPr hy-sBu iPr iPr iPr M
M1 iPr sBu hy-sBu iPr iPr iPr M
M2 iPr hy-sBu sBu iPr iPr iPr M
N sBu sBu hy-sBu iPr iPr iPr M
O1 iPr iPr sBu iBu iPr iPr M
O2 iPr iPr sBu iPr iBu iPr M
O3 iPr iPr sBu iPr iPr iBu M
P1 iPr iPr iPr hy-Et iPr iPr M
P2 iPr iPr iPr hy-Et iBu iPr M
a Enniatin E is produced by the organism as a mixture of the two listed diast
This journal is ª The Royal Society of Chemistry 2011E. coli was fully N-methylated, but remained associated with the
cells.
Heterologous expression of CODS, and heterologous produc-
tion of CODs in strains that are easier to manipulate genetically
than the native fungal producers will facilitate the enzymatic
characterization of CODS and their engineered variants, and will
promote the combinatorial biosynthesis of novel CODs.7 Structural diversification of CODs
7.1 Natural COD congeners
Twenty-seven natural enniatin congeners have been isolated and
characterized to date from various enniatin producer fungi1 M2 M3 First isolated from Ref.
e Me Me Fusarium orthoceras var. enniatinum
ETH 1523 and F. scirpi ETH 1536
152
e Me Me Fusarium roseum acuminatum 153
e Me Me Fusarium spp. ETH 4363 and ETH 1574 152
e Me Me Fusarium roseum acuminatum 153
Me Me Fusarium avanaceum 33
H Me Fusarium avanaceum 33
e Me Me Fusarium spp.ETH4363andETH1574 152
e Me Me Fusarium sp. FO-1305 24
e Me Me Fusarium sp. FO-1305 24
e Me Me Fusarium sp. FO-1305 24
e Me Me Halosarpheia sp. strain 732 47
e Me Me Verticillium hemipterigenum BCC 1449 144
e Me Me Verticillium hemipterigenum BCC 1449 144
e Me Me Verticillium hemipterigenum BCC 1449 144
e Me Me Fusarium sp. strain F31 142
e Me Me Fusarium sp. strain F31 142
e Me Me Fusarium sp. strain F31 142
e Me Me Fusarium sp. strain F31 142
e Me Me Unidentified fungus (BCC 2629) 154
e Me Me Unidentified fungus (BCC 2629) 154
e Me Me Unidentified fungus (BCC 2629) 154
e Me Me Unidentified fungus (BCC 2629) 154
e Me Me Verticillium hemipterigenum BCC 1449 46
e Me Me Verticillium hemipterigenum BCC 1449 46
e Me Me Verticillium hemipterigenum BCC 1449 46
e Me Me Fusarium acuminatum
(Gibberella acuminata)
143
e Me Me Fusarium acuminatum
(Gibberella acuminata)
143
ereomers that were not named separately.24
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View Article Online(Table 3). Enniatin A and B were first isolated in Fusarium
orthoceras var. enniatinum, F. scirpi and two other Fusarium spp.,
by Plattner and coworkers137 in a screening for new antibiotics.
Fusarium sp. FO-1305 produces enniatin D, E and F, identified
because of their strong acyl-CoA:cholesterol acyltransferase
(ACAT) inhibition (Section 2.2).24 The enniatin congeners A, A1,
B, B1 and B2 display cytotoxic activity against two human cell
lines (the hepatocellular carcinoma line Hep G2 and the fibro-
blast-like fetal lung cell line MRC-5).33 With more powerful
analytical methods, more natural enniatin analogs were discov-
ered in a shorter time, including the recently described enniatins
H, I and MK1886, which possess anti-HIV activity.27
The cylcooctadepsipeptides of the PF1022 family are produced
by Mycelia sterilia (Rosellinia sp.), with PF1022A as the main
metabolite.61 The PF1022 congeners consist of four L-Leu resi-
dues, but differ in their D-hydroxycarboxylic acid content. Thus,
PF1022A-D and F differ in the number of D-PheLac and D-Lac
residues occupying the hydroxycarboxylic acid positions (Table
4). In contrast, PF1022E and PF1022-202 both contain two D-
Lac, but with one or both D-PheLac positions replaced by p-
hydroxy-D-PheLac.
Beauveria bassianaARSEF 4122 produces beauvericin A and B,
with (2R,3S)-2-hydroxy-3-methylpentanoate (D-2-hydroxy-3-
methylvalerate, D-Hmv) residues replacing one or two D-Hiv
residues. These analogs were evaluated in an insecticidal assay.138
Beauvericins D (L-Phe replacing one N-methyl-L-Phe residue),
E (L-Leu insteadofoneN-Me-L-Phe residue) andF [(2R)-2-hydroxy-
4-methylpentanoate instead of one D-Hiv] were isolated from
Beauveria sp. FKI-1366 and shown todisplay antifungal activity.28,297.2 Unnatural CODs from precursor-directed biosynthesis
Precursor-directed biosynthesis139 utilizes the power of chemical
synthesis to generate precursor analogs that can be processed toTable 4 Naturally occurring PF1022 congeners
R1 R2
PF 1022A Me Bzl
PF 1022B Bzl Bzl
PF 1022C Me Bzl
PF 1022D Me Me
PF 1022E Me Bzl-p-
PF 1022F Me Me
PF 1022-202 Me Bzl-p-
116 | Nat. Prod. Rep., 2011, 28, 99–124complex ‘‘unnatural products’’ by living cells of the producer
microorganisms. Precursor-directed biosynthesis relies on the
substrate flexibility of native biosynthetic enzymes to recognize
and accept the substrate analogs and to fully process the resulting
modified intermediates. The substrate analogs are in direct
competition with the native, intrinsic substrates of the biosyn-
thetic enzymes. This method also presupposes the successful
uptake and compartmentalization of the analogs, and has to
contend with the potential toxicity of both the analogs them-
selves and the modified products.
Precursor-directed biosynthesis introduces added complexity
during COD analog production. First, amino acid precursor
analogs may incorporate directly to the amino acid positions in
the COD, or may be converted to the corresponding D-2-
hydroxycarboxylic acid and thus may also replace the
hydroxycarboxylic acid constituents of the COD. Further, each
precursor is used several times during the iterative assembly of
the monomer units. Thus, incorporation of a precursor analog
leads to the production of a COD analog family in which 1, 2
or all 3 (trimeric CODs) or 1, 2, 3 or all 4 (tetrameric CODs) of
the positions for that substrate are replaced by the analog.
Further, when two molecules of the same precursor analog
incorporate into a tetrameric COD, two isomeric products are
produced (one where the replacements took place in adjoining
monomers, and another where the modified and the native
monomers are alternating), due to the possibility of circular
permutation.
Precursor-directed biosynthesis has been assessed by Zocher
and coworkers using the enniatin producers Fusarium scirpi and
F. sambucinum.140 A small set of radioactively labeled hydroxy-
carboxylic acids (DL-2-hydroxy-n-valeric acid, D-2-hydroxy-3-
methyl-n-valeric acid, DL-hydroxybutyric acid [DL-Hbu], and
D-Lac) and L-amino acids (L-2-amino butyric acid [L-Abu], L-Ala,
L-Cys, L-Thr, L-Ser and L-allylglycine) were separately fed inR3 R4
Me Bzl
Bzl Bzl
Bzl Bzl
Me Bzl
OH Me Bzl
Me Me
OH Me Bzl-p-OH
This journal is ª The Royal Society of Chemistry 2011
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View Article Onlinea single dose (10 mM, final concentration) to the cultures after 72
h of fermentation. The cultivation was continued for another two
days. The formation of enniatin analogs was analyzed by HPLC,
mass spectrometry and NMR spectroscopy. Amongst the
hydroxycarboxylic acids, formation of product analogs could
only be observed with D-Lac and DL-Hbu. In contrast, the amino
acids L-Ala, L-Abu, L-Ser and L-Thr all yielded new enniatins.
The ‘‘unnatural’’ all-D-Lac enniatin was found to have anthel-
minthic properties.141 Subsequently, L-Ala, L-Thr and L-Abu-
containing natural enniatins (enniatin J1-3,K, P1/2) have also
been isolated from Fusarium sp. strain F31 and Fusarium acu-
minatum (Gibberella acuminata).142,143
Precursor-directed biosynthesis was also used to produce
enniatin analogs, using the insect pathogenic fungus Verticillium
hemipterigenum BCC 1449 as the producing organism.144 This
strain biosynthesizes enniatins B (trimer of D-Hiv–L-Val), B4 (one
L-Leu and two L-Val as the amino acid constituents), H (one D-
Hmv and two D-Hiv as the hydroxycarboxylic acids), and I (two
D-Hmv and one D-Hiv as the hydroxycarboxylic acid constitu-
ents, Table 3). Upon feeding L-Leu, the production of enniatin
B4 was increased, and the fermentations also yielded enniatins G
(two L-Leu and one L-Val as the amino acids) and minor amounts
of enniatin C (three L-Leu as the amino acid constituents).
Feeding L-Ile increased the production of enniatins H and I, and
led to the production of the new enniatin analogMK1688 (trimer
of D-Hmv–L-Val). Thus, L-Leu is readily accepted by the amino
acid-activating A2 domain of the V. hemipterigenum enniatinFig. 6 Precursor-directed biosyn
This journal is ª The Royal Society of Chemistry 2011synthetase in vivo, but not used as a precursor for the hydroxy-
carboxylic acid positions in enniatin. Conversely, L-Ile serves as
an alternative substrate for D-hydroxycarboxylic acid biosyn-
thesis, and for the subsequent incorporation into enniatin by the
hydroxycarboxylic acid-activating A1 domain. However, L-Ile is
apparently not utilized in vivo as an alternative amino acid
precursor by the CODS. All the isolated enniatin analogs were
evaluated for their antiplasmodial, antimycobacterial, and
cancer cell cytotoxic activities.
Nilanonta et al.15 have used the hypocrealean entomopath-
ogen Paecilomyces tenuipes BCC 1614 to produce beauvericin
analogs (Fig. 6). Feeding L-Ile (2S,3S) or D-allo-Ile (2R,3S) led to
the production of beauvericins A, B and C with one, two or all
three D-Hiv positions replaced by (2R,3S)-Hmv. Feeding D-Ile
(2R,3R) or L-allo-Ile (2S,3R) provided allo-beauvericins A, B,
and C, featuring one, two or three (2R,3R)-Hmv residues. These
experiments are congruent with the conversion of all four Ile
diastereomers to the 2-ketocarboxylic acid, and to the stereo-
specific reduction of this intermediate to the corresponding (2R)-
hydroxycarboxylic acid, with retention of configuration at the
3-position. Both (2R,3S)- and (2R,3R)-Hmv are accepted as
alternative substrates by the hydroxycarboxylic acid-activating
A1 domain of the P. tenuipes beauvericin synthetase in vivo.
Conversely, none of the Ile diastereomers are acceptable in vivo
substrates to replace L-Phe in beauvericin. The new beauvericin
analogs showed similar antimycobacterial, antiplasmodial and
cancer cell antiproliferative activities to that of beauvericin.thesis of beauvericin analogs.
Nat. Prod. Rep., 2011, 28, 99–124 | 117
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View Article OnlinePrecursor-directed biosynthesis was also applied to produce
beauvericin analogs with Beauveria bassianaATCC 7159 (Fig. 6),
using 30 potential precursor analogs of D-Hiv and L-Phe.145
Feeding L-Ile afforded beauvericins A, B and C: similar experi-
ments yielded the same products in Paecilomyces tenuipes.144
However, the BbBEAS beauvericin synthetase proved to be
rather fastidious in vivo, with only a few other precursor analogs
accepted. Thus, D-Hiv could be replaced only by (2R)-2-
hydroxybutyric acid (D-Hbu) to yield beauvericins G1, G2 and G3
featuring one, two or three D-Hbu moieties. As expected, the
(2S)-isomer (L-Hbu) was not accepted by the system. L-Phe could
only be substituted by 2-fluoro or 3-fluoro analogs of Phe to yield
the beauvericin I1–3 and H1–3 series, respectively. Both the L and
D isomers of these amino acid precursor analogs were readily
utilized by the cells, but the synthetase itself seemed to be
stereospecific, as the final beauvericin analogs contained amino
acids with only the L configuration. This suggested that the
substrates underwent epimerization in the cells prior to incor-
poration into the COD. The isolated novel beauvericin analogs
were evaluated for cancer cell antiproliferative and cell motility
inhibitory activities. These two bioactivities were affected to
a different degree by the structural changes, suggesting that it
might be possible to separately optimize cytotoxicity and hap-
totaxis inhibition in future beauvericin analogs.145
Precursor-directed biosynthesis of unnatural PF1022 deriva-
tives in Mycelia sterilia (Rosellinia sp.) was only successful with
p-nitro-PheLac and p-nitro-L-Phe (this latter precursor analog
undergoes in vivo deamination and ketoreduction to p-nitro-
PheLac). The feeding of 10–70 mM of these precursors yielded
up to 40% of PF 1022-268 (the monosubstituted p-nitro-PheLac
derivative) and up to 10% of the desired disubstituted p-nitro-
PheLac derivative, PF 1022-220 (the yield of PF 1022A¼ 100%).
PF 1022-220 constitutes a potentially useful intermediate that
might significantly simplify the production process for emodep-
sid, an important semisynthetic anthelminthic agent.70 However,
the low yields of precursor-directed biosynthesis currently
prohibit the scale-up of this process to industrial production (W.
Weckwerth, Doctoral Thesis, TU Berlin, 1998, and M. Krause,
Doctoral Thesis, TU Berlin, 1998).
As these examples show, the success of precursor-directed
biosynthesis experiments in CODS systems is currently not
predictable. Substrate promiscuity does not derive merely from
substrate recognition and activation by the A domains. Rather,
successful production of unnatural CODs requires correct pro-
cessing of the precursors and intermediates by the C domains and
the subsequent modifying enzymes. The products should also be
acceptable for the COD export system, and the unnatural CODs
should not be overly toxic to the producer cells. More knowledge
and expertise has to be gathered to make precursor-directed
biosynthesis of CODs more predictable, reliable, and economical
on the industrial scale.7.3 Mutasynthesis and combinatorial mutasynthesis
Mutasynthesis is one of the most successful methods of combi-
natorial biosynthesis that has been applied to many natural
product classes including polyketides, siderophores, nucleosides,
aminocoumarins and nonribosomal peptides.139,146–148 Mutasyn-
thesis couples the power of chemical synthesis to generate118 | Nat. Prod. Rep., 2011, 28, 99–124structurally diverse analogs of biosynthetic precursors or inter-
mediates (the so-called ‘‘mutasynthons’’) with the ability of
genetic engineering to create appropriate mutants that are
blocked in the biosynthesis or utilization of the natural (endog-
enous) precursors or intermediates. While mutasynthesis was
first demonstrated 40 years ago,149 recent developments in
synthetic techniques, the availability of large commercial
compound libraries, and advances in genetic and genomic tech-
niques led to a renaissance of this approach in both the biotech
industry and the academic community.139,146–148 Mutasynthesis
improves on precursor-directed biosynthesis by removing
competition between the synthetic analog and the endogenous
precursor, thus allowing the uncontested incorporation of the
mutasynthon. It also simplifies the isolation of the resulting
unnatural products by eliminating the biosynthesis of the native
natural product. For CODs, this unchallenged incorporation
means that instead of obtaining a COD analog family in which
the native precursor postions are variably replaced by the
precursor analog, the result being a single unnatural product
bearing substitutions at all expected positions.
Xue et al. have used a kivr mutant of Beauveria bassiana
ATCC 7159 for the mutasynthetic production of novel beau-
vericin analogs.132 This strain lacks ketoisovalerate reductase,
and thus it is unable to produce D-Hiv or similar branched-chain
2-hydroxycarboxylic acids as precursors for beauvericin
biosynthesis, leading to a complete block in beauvericin (and
bassianolide) biosynthesis. From five commercially available 2-
hydroxycarboxylic acids (Hbu, DL-Lac, hydroxyisocaproic acid,
mandelate, and cyclohexyllactate), only D-Hbu restored COD
biosynthesis in B. bassiana, leading to the exclusive and high-titer
production of beauvericin G3. This analog has previously been
detected during precursor-directed biosynthesis, but in substan-
tially lower yields.145 Feeding synthetic DL-2-hydroxy-3-methyl-
valeric acid (DL-Hmv) to the kivr mutant strain was found to
support the exclusive production of the known analog beauver-
icin C in a good yield. This analog had been previously observed
in small amounts in precursor-directed biosynthesis with wild-
type beauvericin producer strains.15,145
To further increase the structural variety of beauvericin
analogs, Xu et al. have conducted simultaneous feeding of
precursor analogs in pairwise combinations using the kivr
knockout B. bassiana strain, in a procedure dubbed ‘‘combina-
torial mutasynthesis’’ (Fig. 7).132 Such scrambling with two
precursor analogs would not have been practical using the wild-
type strain, as the presence of the competing native precursors
and precursor analogs would have led to a very large number of
possible combinations and circular permutations along the COD
macrocycle. Such a complex product mixture would have been
challenging to separate, and each analog might have been present
only in minor amounts. In contrast, combinatorial mutasyn-
thesis significantly simplified product profiles: the fed hydroxy-
carboxylic acids completely substituted the D-Hiv positions of
beauvericin, while the Phe analogs replaced 0, 1, 2, or all 3 Phe in
the products. To demonstrate this principle, the D-Hiv analogs D-
Hbu and DL-Hmv, and the Phe analogs 3-fluoro-L-Phe and 2-
fluoro-L-Phe, whose acceptability to this strain had already been
shown,132,145 were used for this study. Combinatorial mutasyn-
thesis with these four precursor analogs yielded 14 new beau-
vericin analogs belonging to five novel series. Importantly, inThis journal is ª The Royal Society of Chemistry 2011
Fig. 7 Mutasynthesis and combinatorial mutasynthesis of beauvericin analogs.
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View Article Onlineseveral product analogs, all hydroxycarboxylic acid and amino
acid positions of beauvericin were completely replaced by the fed
mutasynthons. Nine isolated analogs and three beauvericin
analog mixtures that could not be separated under standard
conditions were evaluated for cancer cell antiproliferative and
cell motility inhibitory activities. As before, variation of the two
activities due to the structure changes was not strictly parallel,
indicating that more drastic structural alterations of the beau-
vericin scaffold may help to disconnect the antiproliferative and
anti-haptotactic activities.7.4 In vitro biosynthesis (‘‘total biosynthesis’’) of COD analogs
using purified enzymes
The in vitro reconstitution of enniatin biosynthesis was first
achieved with purified ESYN from Fusarium oxysporum, using
the natural substrates.79 In an extended approach, Zocher and
coworkers used additional amino acid substrate analogs for the
incorporation of amino acids L-Ala, L-Cys, L-Thr and L-Ser into
the enniatin structure (Fig. 8A).140 Among the hydroxycarbox-
ylic acid substrates, D-Hiv could be replaced by D-Hbu and D-
Lac.140
To learn more about the substrate specificity of the enniatin
CODS and to create a bigger library of new derivatives by
chemoenzymatic synthesis or total biosynthesis, various hydroxy-
carboxylic acidswith linear, branched and cyclic side chains – up toThis journal is ª The Royal Society of Chemistry 2011seven carbon atoms and various functional groups, e.g. halogens,
hydroxy and thioether groups – were chemically synthesized and
tested in an in vitro assay with the purified ESYN from F. oxy-
sporum. Surprisingly, some of the hydroxycarboxylic acid
substrates proved to be as good substrates as D-Hiv. Thus, D-Hiv
could be efficiently replaced by D-chlorolactate, D-bromolactate, D-
propargyl lactate, and D-Hbu, whereas the extension of the
aliphatic side chain decreased product yield (Fig. 8A). From these
findings, the binding pocket is proposed to accommodate alkyl
chain residues with a minimum of two carbon atoms (D-Hbu), but
with a maximum of three carbons in linear and four carbons in
branched chains.No substrate activationwas found for polar, ionic
or aromatic hydroxycarboxylic acid side chains.89
Similar to that with the enniatin synthetase FoESYN, the
purified RsPFSYN was also used to perform in vitro total
biosynthesis. The naturally found product distributions in
fermentations could be reproduced in vitro with the natural
substrates.61 Since the observed substrate spectrum of RsPFSYN
includes two sterically and electronically very different
hydroxycarboxylic acids, D-Lac and D-PheLac, a certain
substrate promiscuity was expected from this enzyme. Various
hydroxycarboxylic acids were synthesized and tested with
RsPFSYN for the enzymatic assembly of PF1022 analogs, with
the range of synthetic substrates extended to >40 aromatic and
aliphatic hydroxycarboxylic acids. The results showed that
a large variety of aliphatic and aromatic hydroxycarboxylic acidsNat. Prod. Rep., 2011, 28, 99–124 | 119
Fig. 8 Total biosynthesis of COD analogs. Incorporation of different synthetic 2-hydroxycarboxylic acids (only the side chains shown), replacing the
side chains (represented as small circles) in A. enniatin, and B. PF 1022. The percentages describe the enzyme activity in kcat,app in comparison to the
natural substrate (enniatin: D-Hiv; PF1022: D-PheLac for the aromatic and D-Lac for the aliphatic precursors, respectively).
Pu
bl
ish
ed
 o
n 
20
 O
ct
ob
er
 2
01
0.
 D
ow
nl
oa
de
d 
on
 0
1/
04
/2
01
6 
07
:5
9:
45
. 
View Article Onlinewere indeed acceptable as substrates (Fig. 8B). A strong corre-
lation has been observed between the substrate tolerances of
FoESYN and RsPFSYN towards aliphatic hydroxycarboxylic
acids. Among the aromatic PF1022 derivatives obtained, the
most interesting ones contained heterocycles (e.g. thiophene), or
functionalized phenyl rings (e.g. a perfluorinated analog). While
no clear rules for the substrate specificity of RsPFSYN could be
deduced, the substrate tolerance seemed to increase for aromatic
residues with lesser steric demand, or for precursors with
decreased rotational freedom at the b-position.90
Overall, a number of truly unnatural enniatins and PF1022
derivatives were generated using in vitro biosynthesis. Such
derivatives could facilitate further semi-synthetic modification,
for example by Sonogashira coupling at the alkyne functional-
ities.150 Remarkably, RsPFSYN has an extended substrate
spectrum towards aromatic residues compared to FoESYN, but
neither of these CODSs is able to accept hydroxycarboxylic acids
with polar or charged side chains. Nevertheless, both enzymes
display a potential for the generation of large COD libraries, at
least in vitro. A significant disadvantage of this chemoenzymatic
approach is that only small amounts of CODs are obtained in
routine experiments, and scale-up of the reactions is difficult.
However, as opposed to precursor-directed biosynthesis and
mutasynthesis, in vitro biosynthesis is not limited by substrate
uptake or catabolism by the cell, nor by precursor or product
toxicity issues.Fig. 9 Biosynthesis of PF1022 analogs by precursor supply pathway
engineering.7.5 Combinatorial biosynthesis by precursor supply pathway
engineering
Modulation of precursor availability has been shown to alter the
yields of natural congeners of CODs and to support the
biosynthesis of novel analogs during precursor-directed120 | Nat. Prod. Rep., 2011, 28, 99–124biosynthesis, mutasynthesis, and total biosynthesis, as described
above. Modulation of the availability of intrinsic precursor pools
during in vivo biosynthesis of CODs by metabolic engineering,
and the resulting direct biosynthetic production of COD analogs,
has only been reported in the case of PF1022s (Fig. 9).151 Thus,
a chorismate mutase-deficient strain of the PF1022 producer
Rosellinia sp. has been transformed with three genes from
Streptomyces venezuelae that allow the biosynthesis of p-ami-
nophenylpyruvate from chorismate. Knockout of the cmu1
chorismate mutase gene disrupted the biosynthesis of the PF1022
precursor D-PheLac (and also that of L-Phe) from chorismate.
However, this mutation did not completely eliminate D-PheLac
biosynthesis: deamination of medium-derived Phe to phenyl-
pyruvate, followed by dehydrogenation, could still supply some
of this precursor. Consequently, the cmu1 knockout strain still
produced PF1022A, albeit at a significantly reduced level. TheThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlinecmu1 mutation nevertheless allowed the more efficient chan-
neling of chorismate towards p-aminophenylpyruvate by the
introduced heterologous pathway. The resulting p-amino-
phenylpyruvate was apparently converted to p-amino-D-PheLac
by an uncharacterized endogenous enzyme of Rosellinia sp.: this
analog of D-PheLac has been shown to be acceptable for the
RsPFSYN PF1022 synthetase.61,90 The engineered strain was
shown to produce PF1022-269 and PF1022-260 (one or both D-
PheLac replaced by p-amino-D-PheLac, respectively). Surpris-
ingly, the strain also produced PF1022-268 and PF1022-220 (one
or both D-PheLac replaced by p-nitro-D-PheLac), due to an
adventitious oxidation of the amino group to a nitro function-
ality. Although the yield of the PF1022 analogs was low, the
engineered strain secreted substantial amounts of the aromatic
hydroxycarboxylic acids into the medium, indicating that the
heterologous precursor biosynthetic pathway was relatively
efficient in producing the modified substrate. Direct biosynthetic
production of PF1022 analogs with para-position-specific
modifications of the benzene ring may allow a large range of
further semi-synthetic chemical modifications. It might also
replace a conventional synthetic scheme for the nitration of
PF1022A that has a low specificity, uses toxic reagents, and is
relatively costly.1518 Conclusions
Cyclooligomer depsipeptide natural products are produced by
fungi of the Hypocreomycetidae and the Xylariomycetidae, both
in the class Sordariomycetes. These compounds function as
mycotoxins and potential virulence factors in their native
context, but may be harnessed as antibiotics, insecticides,
anthelminthics, herbicides, antitumor agents, and chemo-
sensitizers by the pharmaceutical and the agribusiness industries.
They may also serve as cholesterol biosynthesis inhibitors,
repress amyloid plaque formation, or arrest the spread of tumors
by inhibiting directional cell migration. Fungal COD biosyn-
thesis involves cyclooligomer depsipeptide synthetases (CODSs),
Type B NRPS enzymes that conduct the programmed iterative
assembly of oligopeptidol monomer units. These CODS also
catalyze the recursive ligation and cyclization of the monomers in
a concerted cyclooligomerization process that involves the
formation of intra- and intermolecular ester bonds. Fungal COD
biosynthesis has been studied for over 30 years, starting with the
isolation of active CODS enzymes from the producer fungi, and
in vitro reconstitution of COD synthesis using appropriate
substrates. Isolation of the corresponding synthetase genes
allowed heterologous expression of CODS and/or their enzy-
matically active fragments for further biochemical and biosyn-
thetic studies, and for the production of the CODs themselves in
a prokaryotic host in a heterologous biocatalytic process. The
isolated CODS genes have revealed interesting mechanistic
differences between fungal and bacterial CODSs, indicating that
the biosynthesis of CODs has a polyphyletic origin. A variety of
combinatorial biosynthetic methods, including precursor-
directed biosynthesis, mutasynthesis, combinatorial mutasyn-
thesis, and total biosynthesis, as well as genome mining for
putative CODS-encoding genes in sequenced fungal genomes,
promises to significantly extend the diversity of this interesting
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